k141_20495_1	SARG|gi|803568669|ref|WP_046077412.1|	34.4	247	308	648	3.70e-32	124
k141_20495_1	SARG|gi|446110352|ref|WP_000188207.1|	34.4	247	308	648	3.70e-32	124
k141_20495_1	SARG|YP_002382193	34.4	247	308	648	3.70e-32	124
k141_20495_1	SARG|gi|803575554|ref|WP_046081557.1|	34.4	247	308	648	3.70e-32	124
k141_20495_1	SARG|gi|446110351|ref|WP_000188206.1|	34.4	247	308	648	3.70e-32	124
k141_20495_1	SARG|gi|754927849|ref|WP_042284850.1|	35.5	220	308	648	3.76e-30	119
k141_20495_1	SARG|gi|757782629|ref|WP_043001213.1|	35.9	220	308	648	1.28e-29	117
k141_20495_1	SARG|gi|992390012|ref|WP_061077002.1|	35.9	220	308	648	1.28e-29	117
k141_20495_1	SARG|gi|763407609|ref|WP_044264203.1|	35.9	220	308	648	1.28e-29	117
k141_20495_1	SARG|gi|968563772|ref|WP_058587854.1|	35.9	220	308	648	1.74e-29	117
k141_133369_5	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.8	229	320	255	4.21e-26	103
k141_133369_5	SARG|gi|835330218|ref|WP_047457825.1|	31.7	230	320	648	1.41e-23	100
k141_133369_5	SARG|YP_001453760	31.7	230	320	648	1.41e-23	100
k141_133369_5	SARG|gi|968563772|ref|WP_058587854.1|	32.0	231	320	648	6.33e-23	98.2
k141_133369_5	SARG|gi|992390012|ref|WP_061077002.1|	32.0	231	320	648	6.33e-23	98.2
k141_133369_5	SARG|Q83LR7	31.7	230	320	648	8.54e-23	97.8
k141_133369_5	SARG|gi|647325472|ref|WP_025760953.1|	31.7	230	320	648	8.54e-23	97.8
k141_133369_5	SARG|gi|647323678|ref|WP_025760497.1|	31.7	230	320	648	8.54e-23	97.8
k141_133369_5	SARG|gi|754927849|ref|WP_042284850.1|	31.3	230	320	648	8.54e-23	97.8
k141_133369_5	SARG|gi|757782629|ref|WP_043001213.1|	32.0	231	320	648	1.15e-22	97.4
k141_133369_6	SARG|gb|ADZ12699.1|ARO:3005091|RanA	30.6	222	328	258	7.01e-24	97.4
k141_133369_6	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	26.1	230	328	579	4.04e-11	62.8
k141_133369_6	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	27.1	229	328	579	5.40e-10	59.3
k141_133369_6	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.3	253	328	550	9.35e-10	58.5
k141_82273_1	SARG|gi|895981299|ref|WP_049056431.1|	35.6	233	254	648	7.64e-42	150
k141_82273_1	SARG|gi|823281237|ref|WP_047037467.1|	35.6	233	254	648	7.64e-42	150
k141_82273_1	SARG|gi|895967513|ref|WP_049046752.1|	35.6	233	254	648	7.64e-42	150
k141_82273_1	SARG|gi|779903733|ref|WP_045374054.1|	35.6	233	254	648	7.64e-42	150
k141_82273_1	SARG|gi|695793471|ref|WP_032707680.1|	36.1	230	254	648	3.79e-41	148
k141_82273_1	SARG|gi|823302270|ref|WP_047057473.1|	35.7	230	254	648	5.21e-41	147
k141_82273_1	SARG|gi|976146774|ref|WP_059305359.1|	35.7	230	254	648	5.21e-41	147
k141_82273_1	SARG|gi|1022664304|ref|WP_063420886.1|	35.7	230	254	648	5.21e-41	147
k141_82273_1	SARG|gi|823309640|ref|WP_047064288.1|	35.7	230	254	648	5.21e-41	147
k141_82273_1	SARG|gi|505807117|ref|WP_015704872.1|	35.7	230	254	648	5.21e-41	147
k141_82273_4	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	29.8	225	263	574	5.85e-18	82.0
k141_82273_4	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	30.8	227	263	579	2.65e-17	80.1
k141_82273_4	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.0	226	263	579	6.53e-17	79.0
k141_82273_4	SARG|gb|CDO61516.1|ARO:3003949|efrB	26.0	208	263	362	3.63e-13	67.4
k141_82273_4	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	219	263	655	1.64e-08	53.9
k141_82273_4	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	219	263	655	5.26e-08	52.4
k141_82273_4	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.9	219	263	655	5.26e-08	52.4
k141_82273_4	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	219	263	655	5.26e-08	52.4
k141_82273_4	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.0	219	263	655	1.68e-07	50.8
k141_82273_4	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.0	219	263	655	1.68e-07	50.8
k141_31230_6	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	26.9	308	339	346	1.39e-16	78.6
k141_31230_7	SARG|gi|740856590|ref|WP_038641842.1|	30.9	223	235	648	5.77e-23	95.9
k141_31230_7	SARG|gi|922960663|ref|WP_053388845.1|	30.9	223	235	648	5.77e-23	95.9
k141_31230_7	SARG|gi|491270241|ref|WP_005128370.1|	30.5	223	235	648	1.44e-22	94.7
k141_31230_7	SARG|gi|507086196|ref|WP_016156937.1|	30.5	223	235	648	1.44e-22	94.7
k141_31230_7	SARG|gi|851902043|ref|WP_048212057.1|	30.5	223	235	648	1.44e-22	94.7
k141_31230_7	SARG|gi|992380339|ref|WP_061067665.1|	30.5	223	235	648	1.44e-22	94.7
k141_31230_7	SARG|gi|757799695|ref|WP_043016897.1|	30.5	223	235	648	1.96e-22	94.4
k141_31230_7	SARG|gi|1045891604|ref|WP_065554100.1|	30.5	223	235	648	1.96e-22	94.4
k141_31230_7	SARG|gi|507082903|ref|WP_016153652.1|	30.5	223	235	648	1.96e-22	94.4
k141_31230_7	SARG|gi|696368937|ref|WP_032943949.1|	29.9	231	235	648	2.66e-22	94.0
k141_31230_8	SARG|gb|AAC75271.1|ARO:3003952|yojI	27.8	194	285	547	3.08e-12	65.5
k141_92508_8	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	38.6	223	289	255	4.52e-46	154
k141_92508_8	SARG|gi|500194536|ref|WP_011867743.1|	29.5	224	289	306	2.98e-29	112
k141_92508_8	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	29.2	240	289	343	4.02e-27	107
k141_906_2	SARG|YP_001373621	28.8	236	301	318	1.19e-23	97.4
k141_906_2	SARG|gb|ADZ12699.1|ARO:3005091|RanA	28.0	211	301	258	2.04e-20	87.4
k141_906_8	megares|MEG_1583|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA_1	27.9	183	208	220	1.58e-18	79.3
k141_906_8	SARG|K00544.gene.p01	27.9	183	208	220	1.58e-18	79.3
k141_906_8	NCBI|WP_063843212.1|1|1|catA5|catA5|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_A-5_phenicol_O-acetyltransferase|AMR|phenicol	26.0	204	208	220	8.06e-14	66.6
k141_906_11	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.8	182	188	255	6.35e-18	77.8
k141_41713_5	megares|MEG_1289|Drugs|beta-lactam|Penicillin_binding_protein_regulator|BLAI_1	33.1	118	124	126	7.27e-20	77.8
k141_41713_5	NCBI|WP_000369214.1|1|1|mecI_of_mecA|mecI_of_mecA||2|METHICILLIN|beta-lactam|mecA-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	28.7	115	124	123	4.81e-17	70.5
k141_41713_5	NCBI|WP_000369216.1|1|1|mecI_of_mecA|mecI_of_mecA||2|METHICILLIN|beta-lactam|mecA-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	28.7	115	124	123	4.81e-17	70.5
k141_41713_5	NCBI|WP_000196386.1|1|1|mecI_of_mecC|mecI_of_mecC||2|METHICILLIN|beta-lactam|mecC-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	28.8	118	124	124	2.42e-14	63.5
k141_82895_11	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.2	548	576	575	5.11e-122	370
k141_82895_11	SARG|gb|AAK76137.1|ARO:3000024|patA	37.1	510	576	564	4.78e-102	318
k141_82895_11	SARG|gb|AAC74000.1|ARO:3003950|msbA	29.3	569	576	582	1.30e-71	239
k141_82895_11	SARG|gi|493394434|ref|WP_006350564.1|	29.5	583	576	602	8.19e-64	219
k141_82895_11	SARG|gi|648667297|ref|WP_026359044.1|	30.1	575	576	605	2.32e-63	218
k141_82895_11	SARG|gi|928900436|ref|WP_053931243.1|	29.7	566	576	600	2.93e-63	217
k141_82895_11	SARG|gi|664579989|ref|WP_031094015.1|	29.7	566	576	601	2.99e-63	217
k141_82895_11	SARG|gi|948137056|ref|WP_056795395.1|	29.6	575	576	602	5.88e-63	216
k141_82895_11	SARG|gi|695842130|ref|WP_032755430.1|	30.6	543	576	603	3.09e-62	214
k141_82895_11	SARG|gi|664042835|ref|WP_030582300.1|	30.0	550	576	604	4.37e-62	214
k141_82895_12	SARG|gb|AAK76136.1|ARO:3000025|patB	34.3	569	583	588	1.22e-104	326
k141_82895_12	SARG|gb|AYV52072.1|ARO:3002882|lmrD	34.9	518	583	664	2.24e-100	317
k141_82895_12	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	34.0	579	583	579	1.56e-94	300
k141_82895_12	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	33.4	580	583	579	3.07e-94	299
k141_82895_12	SARG|gb|CDO61516.1|ARO:3003949|efrB	45.9	333	583	362	6.57e-92	286
k141_82895_12	SARG|gi|944152509|ref|WP_055644808.1|	32.3	572	583	616	1.79e-91	293
k141_82895_12	SARG|gi|921231571|ref|WP_053176464.1|	31.9	573	583	620	1.07e-90	291
k141_82895_12	SARG|gi|926345639|ref|WP_053677539.1|	32.1	573	583	620	1.07e-90	291
k141_82895_12	SARG|gi|926376632|ref|WP_053705806.1|	32.2	575	583	620	1.07e-90	291
k141_82895_12	SARG|gi|917172177|ref|WP_051778889.1|	31.9	573	583	620	1.50e-90	290
k141_72605_2	ResF|poxtA-Ef_1_WP094899500.1_1	33.1	172	258	538	2.17e-20	89.0
k141_72605_2	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	33.1	172	258	543	2.19e-20	89.0
k141_72605_2	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	33.1	172	258	543	2.19e-20	89.0
k141_72605_2	SARG|gb|AVI44920.1|ARO:3004470|poxtA	32.6	172	258	542	1.27e-17	80.9
k141_72605_2	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	32.6	172	258	544	1.27e-17	80.9
k141_72605_2	SARG|gb|AAK76137.1|ARO:3000024|patA	24.7	239	258	564	4.32e-17	79.3
k141_72605_2	SARG|gi|926400371|ref|WP_053728483.1|	27.1	247	258	603	1.64e-15	74.7
k141_72605_2	SARG|gi|930482089|ref|WP_054228897.1|	25.3	245	258	599	4.02e-15	73.6
k141_72605_2	SARG|gi|985844137|ref|WP_060895163.1|	25.3	245	258	599	4.02e-15	73.6
k141_72605_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	23.8	227	258	575	5.34e-15	73.2
k141_1134_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.3	284	374	664	2.75e-57	196
k141_1134_1	SARG|gb|AAK76136.1|ARO:3000025|patB	35.3	312	374	588	6.34e-55	189
k141_1134_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	41.4	239	374	582	2.18e-53	184
k141_1134_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	35.7	277	374	362	4.31e-51	173
k141_1134_1	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	32.0	266	374	574	7.61e-41	150
k141_1134_1	SARG|gi|921979807|ref|WP_053271336.1|	28.3	219	374	648	4.79e-17	81.6
k141_1134_1	SARG|FR772051.1.gene9.p01	25.3	288	374	524	5.73e-13	68.9
k141_1134_1	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	27.9	190	374	524	3.16e-11	63.5
k141_144289_14	SARG|gi|749574782|ref|WP_040203616.1|	33.9	218	304	323	1.50e-26	105
k141_144289_14	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	35.2	219	304	343	2.83e-26	105
k141_144289_14	SARG|gi|740152780|ref|WP_037997109.1|	31.6	244	304	322	2.83e-26	104
k141_144289_14	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	35.2	219	304	348	3.05e-26	105
k141_144289_14	SARG|AAY52004	31.3	284	304	322	1.04e-25	103
k141_144289_14	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	32.3	217	304	314	2.43e-25	102
k141_144289_14	SARG|gi|746609237|ref|WP_039635344.1|	30.7	280	304	322	2.76e-25	102
k141_144289_14	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	32.6	236	304	337	4.78e-25	101
k141_144289_14	SARG|DQ018711.1.gene4.p01	29.5	258	304	322	1.01e-24	100
k141_144289_14	SARG|KF478993.1.gene2.p01	32.1	234	304	350	5.42e-24	99.0
k141_134745_7	CARD|gb|CAA79966.1|ARO:3003665|NmcR	37.4	123	311	295	1.50e-12	65.9
k141_134745_13	SARG|gi|895872463|ref|WP_048979698.1|	37.8	222	230	646	1.27e-41	148
k141_134745_13	SARG|gi|779793259|ref|WP_045327301.1|	38.3	222	230	646	1.75e-41	148
k141_134745_13	SARG|gi|556487375|ref|WP_023335108.1|	37.4	222	230	646	2.41e-41	147
k141_134745_13	SARG|gi|974588181|ref|WP_059178476.1|	38.3	222	230	646	2.41e-41	147
k141_134745_13	SARG|gi|981224618|ref|WP_059445588.1|	37.4	222	230	646	2.41e-41	147
k141_134745_13	SARG|gi|779852631|ref|WP_045348970.1|	37.8	222	230	646	2.41e-41	147
k141_134745_13	SARG|gi|836580371|ref|WP_047737758.1|	37.8	222	230	646	2.41e-41	147
k141_134745_13	SARG|gi|798928072|ref|WP_045906664.1|	37.8	222	230	646	2.41e-41	147
k141_134745_13	SARG|gi|836585048|ref|WP_047742322.1|	37.4	222	230	646	2.41e-41	147
k141_134745_13	SARG|gi|746222054|ref|WP_039271209.1|	37.8	222	230	646	2.41e-41	147
k141_93481_15	SARG|FN594949.1.gene24.p01	41.5	147	607	640	1.06e-25	110
k141_93481_15	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	41.5	147	607	640	1.06e-25	110
k141_93481_15	SARG|ZP_03989103	30.8	321	607	639	1.87e-25	110
k141_93481_15	SARG|ABV82118	30.2	321	607	639	5.83e-25	108
k141_93481_15	SARG|ABV82120	30.5	321	607	639	7.75e-25	108
k141_93481_21	SARG|gb|ADZ12699.1|ARO:3005091|RanA	24.8	210	233	258	4.99e-17	76.6
k141_124403_4	SARG|gb|AAK76137.1|ARO:3000024|patA	24.2	223	235	564	1.66e-10	59.3
k141_124403_4	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	235	235	655	3.15e-10	58.5
k141_124403_4	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	235	235	655	3.15e-10	58.5
k141_124403_4	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	236	235	655	4.25e-10	58.2
k141_124403_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	235	235	655	7.70e-10	57.4
k141_124403_4	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	235	235	655	7.70e-10	57.4
k141_124403_4	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	235	235	655	7.70e-10	57.4
k141_124403_4	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	235	235	655	7.70e-10	57.4
k141_124403_4	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	235	235	655	7.70e-10	57.4
k141_124403_4	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	235	235	655	7.70e-10	57.4
k141_113858_3	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	28.8	212	504	578	1.63e-16	81.3
k141_113858_3	SARG|YP_001588793	28.4	222	504	648	1.31e-15	78.6
k141_113858_3	SARG|gi|487407385|ref|WP_001675419.1|	28.4	222	504	648	3.05e-15	77.4
k141_113858_3	SARG|gi|487661511|ref|WP_001751648.1|	28.4	222	504	648	3.05e-15	77.4
k141_113858_3	SARG|gi|919601241|ref|WP_052893936.1|	28.4	222	504	648	3.05e-15	77.4
k141_113858_3	SARG|YP_002214869	28.4	222	504	648	3.05e-15	77.4
k141_113858_3	SARG|ZP_03074747	28.4	222	504	648	3.05e-15	77.4
k141_113858_3	SARG|gi|923061916|ref|WP_053445667.1|	28.4	222	504	648	3.05e-15	77.4
k141_113858_3	SARG|gi|922019548|ref|WP_053299973.1|	27.9	222	504	648	4.04e-15	77.0
k141_113858_3	SARG|gi|739906046|ref|WP_037756452.1|	32.2	205	504	620	5.16e-15	76.6
k141_83378_5	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	45.2	230	234	228	7.63e-61	189
k141_83378_5	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.3	227	234	232	1.69e-52	168
k141_83378_5	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.4	225	234	231	3.29e-52	167
k141_83378_5	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.7	228	234	232	8.63e-50	161
k141_83378_5	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.7	228	234	232	8.63e-50	161
k141_83378_5	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	40.7	231	234	239	1.49e-49	161
k141_83378_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.4	223	234	219	3.34e-49	159
k141_83378_5	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.6	223	234	229	6.31e-49	159
k141_83378_5	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	39.0	228	234	235	4.22e-48	157
k141_83378_5	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	38.1	226	234	233	2.83e-45	150
k141_83378_6	CARD|gb|ABD30512.1|ARO:3000839|arlS	34.7	222	585	451	3.91e-32	128
k141_83378_6	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	29.8	235	585	384	1.91e-28	116
k141_83378_6	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	29.8	235	585	384	1.91e-28	116
k141_83378_6	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	30.2	235	585	386	2.66e-28	115
k141_83378_6	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	30.2	235	585	386	2.66e-28	115
k141_83378_6	CARD|gb|AAD51347.1|ARO:3003067|smeS	32.3	232	585	467	3.00e-28	117
k141_83378_6	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	29.8	235	585	388	1.25e-27	114
k141_83378_6	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	29.8	235	585	388	1.25e-27	114
k141_83378_6	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	29.8	235	585	386	2.22e-27	113
k141_83378_6	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	29.8	235	585	386	2.22e-27	113
k141_73327_11	SARG|gi|851913025|ref|WP_048215946.1|	34.8	233	246	648	5.24e-40	144
k141_73327_11	SARG|YP_002850060	34.8	233	246	648	5.24e-40	144
k141_73327_11	SARG|gi|489930965|ref|WP_003834285.1|	34.8	233	246	648	5.24e-40	144
k141_73327_11	SARG|gi|696368937|ref|WP_032943949.1|	34.9	232	246	648	7.21e-40	144
k141_73327_11	SARG|gi|851922185|ref|WP_048218206.1|	34.8	233	246	648	7.21e-40	144
k141_73327_11	SARG|gi|696375069|ref|WP_032949617.1|	34.8	233	246	648	7.21e-40	144
k141_73327_11	SARG|gi|489936909|ref|WP_003840216.1|	34.8	233	246	648	7.21e-40	144
k141_73327_11	SARG|gi|489127020|ref|WP_003036815.1|	34.8	233	246	648	7.21e-40	144
k141_73327_11	SARG|gi|507079862|ref|WP_016150620.1|	34.8	233	246	648	7.21e-40	144
k141_73327_11	SARG|gi|949791377|ref|WP_057104572.1|	34.8	233	246	648	7.21e-40	144
k141_1719_10	SARG|gb|AAK76137.1|ARO:3000024|patA	28.7	171	237	564	7.74e-16	75.1
k141_1719_11	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	20.7	237	258	255	5.53e-13	65.9
k141_1719_11	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	22.5	200	258	505	3.37e-08	52.8
k141_1719_11	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	21.5	200	258	504	6.23e-07	48.9
k141_114168_6	SARG|gb|AAG04750.1|ARO:3004077|PmpM	25.5	361	414	477	7.15e-15	75.1
k141_114168_6	NCBI|AAG27731.1|1|1|norM-Burk|norM-Burk|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_NorM|AMR|efflux	25.7	362	414	462	6.50e-11	62.8
k141_144902_2	SARG|gi|803568669|ref|WP_046077412.1|	38.0	245	265	648	9.02e-36	133
k141_144902_2	SARG|gi|446110352|ref|WP_000188207.1|	38.0	245	265	648	9.02e-36	133
k141_144902_2	SARG|YP_002382193	38.0	245	265	648	9.02e-36	133
k141_144902_2	SARG|gi|803575554|ref|WP_046081557.1|	38.0	245	265	648	9.02e-36	133
k141_144902_2	SARG|gi|446110351|ref|WP_000188206.1|	38.0	245	265	648	9.02e-36	133
k141_144902_2	SARG|gi|502669352|ref|WP_012905216.1|	35.1	239	265	648	1.85e-33	127
k141_144902_2	SARG|gi|1035670474|ref|WP_064517458.1|	36.0	239	265	648	1.20e-32	124
k141_144902_2	SARG|gi|1035717981|ref|WP_064557480.1|	35.9	234	265	648	1.20e-32	124
k141_144902_2	SARG|gi|1035706844|ref|WP_064548272.1|	35.5	234	265	648	3.06e-32	123
k141_144902_2	SARG|gi|736472622|ref|WP_034494292.1|	35.0	234	265	648	1.45e-31	121
k141_124900_15	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	31.3	147	419	639	5.37e-14	72.8
k141_124900_16	SARG|L42544.gene.p01	28.3	667	693	651	1.27e-81	271
k141_124900_16	SARG|AAV80410	28.3	667	693	651	2.47e-81	270
k141_124900_16	SARG|NP_348076	27.2	676	693	652	3.74e-76	256
k141_124900_16	SARG|YP_002850805	27.3	675	693	652	1.01e-74	252
k141_124900_16	SARG|AJ514254.gene.p01	27.2	681	693	640	1.09e-74	252
k141_124900_16	SARG|ZP_02952732	27.2	673	693	652	3.75e-73	248
k141_124900_16	SARG|ZP_02632674	27.2	673	693	660	4.40e-73	248
k141_124900_16	SARG|L20800.gene.p01	27.2	673	693	652	1.00e-72	247
k141_124900_16	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.6	684	693	641	2.14e-72	246
k141_124900_16	SARG|AAZ79478	26.6	684	693	657	2.96e-72	246
k141_22045_3	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.5	631	629	655	6.79e-94	301
k141_22045_3	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.5	631	629	655	9.51e-94	301
k141_22045_3	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.4	631	629	655	1.33e-93	301
k141_22045_3	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.5	631	629	655	1.33e-93	301
k141_22045_3	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	633	629	655	1.87e-93	300
k141_22045_3	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.4	631	629	655	3.66e-93	300
k141_22045_3	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.4	631	629	655	3.66e-93	300
k141_22045_3	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.4	631	629	655	3.66e-93	300
k141_22045_3	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.4	631	629	655	3.66e-93	300
k141_22045_3	SARG|gb|AKA86814|ARO:3003746|optrA	31.4	631	629	655	3.66e-93	300
k141_83993_7	SARG|gi|500194536|ref|WP_011867743.1|	36.5	208	287	306	3.59e-39	138
k141_83993_7	SARG|gi|507044560|ref|WP_016115614.1|	33.3	261	287	306	5.03e-39	137
k141_83993_7	SARG|gi|446026113|ref|WP_000103968.1|	33.0	261	287	306	7.06e-39	137
k141_83993_7	SARG|gi|447195835|ref|WP_001273091.1|	36.1	208	287	306	9.90e-39	137
k141_83993_7	SARG|gi|447195836|ref|WP_001273092.1|	35.6	208	287	306	2.73e-38	135
k141_83993_7	SARG|ZP_04081918	35.6	208	287	306	3.82e-38	135
k141_83993_7	SARG|gi|542061059|gb|ERI11611.1|	35.1	208	287	316	6.70e-38	135
k141_83993_7	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	35.9	237	287	307	1.08e-37	134
k141_83993_7	SARG|YP_001373621	33.1	236	287	318	7.39e-37	132
k141_83993_7	SARG|P42332	34.8	207	287	306	2.19e-36	130
k141_135813_2	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	21.5	223	430	397	7.29e-08	53.1
k141_22513_1	SARG|gi|446048013|ref|WP_000125868.1|	37.8	74	88	648	1.93e-10	54.3
k141_22513_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.3	66	88	664	4.26e-06	42.0
k141_22513_18	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.1	221	347	574	8.49e-13	68.2
k141_22513_19	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	38.0	71	179	293	6.02e-08	50.1
k141_22513_19	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	29.5	78	179	307	2.10e-07	48.5
k141_22513_19	SARG|gi|500194536|ref|WP_011867743.1|	32.4	71	179	306	9.57e-07	46.6
k141_22513_19	SARG|gi|542061059|gb|ERI11611.1|	30.0	80	179	316	9.74e-07	46.6
k141_115315_12	NCBI|WP_001284656.1|1|1|blaI_of_Z|blaI_of_Z|regulation|2|beta-lactam|beta-lactam|penicillinase_repressor_BlaI|AMR|beta-lactam	28.1	114	124	126	1.62e-15	66.6
k141_22767_1	SARG|YP_002333394	37.5	104	101	323	8.58e-12	58.5
k141_22767_1	SARG|gi|498515089|ref|WP_010815296.1|	36.5	104	101	323	2.21e-11	57.4
k141_22767_1	SARG|Q47748	36.5	104	101	323	2.21e-11	57.4
k141_22767_1	SARG|gi|985522333|ref|WP_060811962.1|	36.5	104	101	323	2.21e-11	57.4
k141_22767_1	SARG|AF310956.2.gene5.p01	36.5	104	101	323	3.03e-11	57.0
k141_22767_1	SARG|AAF72362	36.5	104	101	323	3.03e-11	57.0
k141_22767_1	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	36.5	104	101	323	3.03e-11	57.0
k141_22767_1	SARG|gb|AAB05626.1|ARO:3002943|vanHB	37.6	101	101	323	3.03e-11	57.0
k141_22767_1	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	32.4	105	101	343	1.10e-10	55.5
k141_22767_1	SARG|gi|740152780|ref|WP_037997109.1|	36.3	102	101	322	1.46e-10	55.1
k141_22767_16	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	40.8	157	161	159	2.06e-36	122
k141_22767_23	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.3	228	231	229	3.08e-54	172
k141_22767_23	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.2	228	231	232	1.53e-52	168
k141_22767_23	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.2	228	231	232	1.53e-52	168
k141_22767_23	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.8	231	231	231	8.40e-52	166
k141_22767_23	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.6	230	231	231	2.38e-51	165
k141_22767_23	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.6	230	231	231	2.38e-51	165
k141_22767_23	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.1	231	231	232	4.89e-51	164
k141_22767_23	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.3	230	231	231	6.72e-51	164
k141_22767_23	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.7	231	231	232	1.96e-50	163
k141_22767_23	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.4	232	231	232	2.76e-50	162
k141_22767_24	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	23.4	282	431	370	1.22e-14	73.9
k141_22767_24	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	23.1	286	431	354	1.47e-14	73.6
k141_22767_24	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	23.8	286	431	352	1.95e-14	73.2
k141_22767_24	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	23.8	286	431	376	2.27e-14	73.2
k141_22767_24	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	23.8	286	431	376	2.27e-14	73.2
k141_22767_24	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	21.3	334	431	386	5.72e-14	72.0
k141_22767_24	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	21.3	334	431	386	5.72e-14	72.0
k141_22767_24	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	22.1	335	431	388	1.03e-13	71.2
k141_22767_24	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	22.1	335	431	388	1.03e-13	71.2
k141_22767_24	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	25.2	250	431	361	1.19e-13	70.9
k141_105161_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	50.5	99	108	582	2.03e-25	97.8
k141_105161_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	43.0	107	108	664	2.72e-22	89.0
k141_105161_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	42.4	99	108	362	8.38e-20	81.3
k141_105161_2	SARG|gb|AAK76136.1|ARO:3000025|patB	40.2	107	108	588	6.40e-19	79.3
k141_105161_3	SARG|gi|1045390184|ref|WP_065479071.1|	25.0	360	375	605	1.62e-21	95.1
k141_105161_13	SARG|YP_002861121	73.1	208	212	212	2.29e-120	339
k141_105161_13	SARG|YP_001785579	73.1	208	212	212	1.88e-119	337
k141_105161_13	SARG|YP_001779894	72.6	208	212	212	2.67e-119	336
k141_105161_13	SARG|YP_001389621	72.1	208	212	212	3.79e-119	336
k141_105161_13	SARG|U19459.gene.p01	73.6	208	212	212	1.54e-118	334
k141_105161_13	SARG|AAG21695	68.2	198	212	214	1.77e-99	286
k141_105161_13	SARG|AF139725.gene.p01	67.7	198	212	214	2.06e-98	283
k141_105161_13	SARG|AAK91782	67.7	198	212	214	4.14e-98	283
k141_105161_13	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	67.7	198	212	214	1.19e-97	281
k141_105161_13	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	67.2	198	212	214	3.39e-97	280
k141_44262_1	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	28.3	237	372	346	2.69e-10	60.1
k141_74584_51	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	34.5	206	231	325	1.23e-31	117
k141_74584_51	SARG|gb|AAA26793|ARO:3003748|oleC	34.5	206	231	325	2.40e-31	116
k141_74584_51	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	35.1	188	231	293	2.30e-25	99.8
k141_74584_51	SARG|gi|736993687|ref|WP_034989673.1|	39.7	58	231	513	1.96e-06	47.0
k141_74584_51	SARG|AF024666.2.gene6.p01	39.7	58	231	513	1.96e-06	47.0
k141_74584_51	SARG|gi|171851258|emb|CAQ04234.1|	37.9	58	231	483	2.57e-06	46.6
k141_95163_1	SARG|gi|500194536|ref|WP_011867743.1|	36.5	208	287	306	2.56e-39	138
k141_95163_1	SARG|gi|447195835|ref|WP_001273091.1|	36.1	208	287	306	1.39e-38	136
k141_95163_1	SARG|gi|507044560|ref|WP_016115614.1|	35.1	208	287	306	1.39e-38	136
k141_95163_1	SARG|gi|446026113|ref|WP_000103968.1|	34.6	208	287	306	1.95e-38	136
k141_95163_1	SARG|gi|542061059|gb|ERI11611.1|	35.6	208	287	316	3.41e-38	135
k141_95163_1	SARG|gi|447195836|ref|WP_001273092.1|	35.6	208	287	306	3.82e-38	135
k141_95163_1	SARG|ZP_04081918	35.6	208	287	306	5.36e-38	135
k141_95163_1	SARG|YP_001373621	34.6	208	287	318	1.45e-36	131
k141_95163_1	SARG|gi|445996708|ref|WP_000074563.1|	34.6	208	287	309	2.34e-36	130
k141_95163_1	SARG|gi|447057509|ref|WP_001134765.1|	34.6	208	287	309	2.34e-36	130
k141_105624_5	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	24.7	364	798	593	4.78e-08	55.5
k141_105624_7	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	39.4	457	458	481	1.43e-96	298
k141_105624_7	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	38.8	456	458	451	7.40e-95	292
k141_105624_7	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	39.0	456	458	451	8.24e-94	290
k141_105624_11	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	29.1	444	427	444	2.02e-40	148
k141_85239_7	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.7	268	383	355	1.20e-19	88.2
k141_85239_7	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.7	268	383	355	1.20e-19	88.2
k141_85239_7	SARG|ACM47285	28.7	268	383	363	1.30e-19	88.2
k141_126530_2	SARG|gi|446048013|ref|WP_000125868.1|	30.4	237	262	648	9.42e-22	93.2
k141_126550_8	SARG|gi|686436876|ref|WP_031922735.1|	26.7	191	257	491	4.21e-09	55.5
k141_126550_8	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	31.1	164	257	568	4.47e-09	55.5
k141_126550_8	SARG|FR772051.1.gene9.p01	21.8	216	257	524	7.80e-09	54.7
k141_126550_8	megares|MEG_4068|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRA_1	24.5	204	257	176	5.37e-08	50.4
k141_126550_8	SARG|gi|686444151|ref|WP_031925491.1|	26.2	191	257	488	5.89e-08	52.0
k141_126550_8	SARG|YP_254220	25.0	204	257	488	5.89e-08	52.0
k141_126550_8	SARG|gi|581672381|gb|EVQ77821.1|	25.7	191	257	394	7.07e-08	51.6
k141_126550_8	SARG|gi|587321226|gb|EWW03298.1|	25.7	191	257	413	7.26e-08	51.6
k141_126550_8	SARG|gi|580336413|gb|EVD62957.1|	25.7	191	257	478	7.81e-08	51.6
k141_126550_8	SARG|YP_001569068	25.7	191	257	488	7.89e-08	51.6
k141_126558_5	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	54.4	1209	1235	1162	0.0	1239
k141_126558_5	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	50.8	1237	1235	1186	0.0	1179
k141_126558_5	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	50.8	1237	1235	1186	0.0	1179
k141_106119_4	SARG|gi|516574297|ref|WP_017949361.1|	35.0	549	583	620	1.14e-89	288
k141_106119_4	SARG|gi|739906046|ref|WP_037756452.1|	34.8	549	583	620	6.17e-89	286
k141_106119_4	SARG|gi|928900436|ref|WP_053931243.1|	33.9	548	583	600	5.65e-88	283
k141_106119_4	SARG|gi|664579989|ref|WP_031094015.1|	33.9	548	583	601	5.79e-88	283
k141_106119_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	34.4	512	583	582	9.96e-88	282
k141_106119_4	SARG|gi|919568551|ref|WP_052871170.1|	35.6	500	583	620	1.29e-87	283
k141_106119_4	SARG|gi|648667297|ref|WP_026359044.1|	33.3	573	583	605	2.46e-87	281
k141_106119_4	SARG|gi|772774655|ref|WP_045322518.1|	33.7	572	583	620	3.54e-87	281
k141_106119_4	SARG|gi|917172177|ref|WP_051778889.1|	35.7	502	583	620	6.95e-87	281
k141_106119_4	SARG|gi|921231571|ref|WP_053176464.1|	35.7	502	583	620	6.95e-87	281
k141_106119_23	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	28.7	689	661	703	1.01e-77	261
k141_86005_1	SARG|gi|446048013|ref|WP_000125868.1|	26.9	234	400	648	4.68e-18	85.1
k141_35074_7	SARG|gi|542061059|gb|ERI11611.1|	30.7	212	504	316	8.55e-14	71.2
k141_35074_7	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	31.7	202	504	293	9.09e-14	70.9
k141_35074_7	SARG|P42332	29.9	211	504	306	1.47e-12	67.4
k141_35074_7	SARG|ABB80128	29.9	211	504	306	1.47e-12	67.4
k141_35074_7	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	29.9	211	504	306	1.47e-12	67.4
k141_35074_7	SARG|gi|445996710|ref|WP_000074565.1|	31.0	210	504	309	1.51e-12	67.4
k141_35074_7	SARG|gi|510143239|gb|AGN36970.1|	29.9	211	504	313	1.56e-12	67.4
k141_35074_7	SARG|gi|445996719|ref|WP_000074574.1|	31.0	210	504	309	2.70e-12	66.6
k141_35074_7	SARG|gi|814314593|emb|CKF49145.1|	30.7	212	504	309	2.70e-12	66.6
k141_35074_7	SARG|gi|488120365|ref|WP_002191762.1|	31.0	210	504	309	3.62e-12	66.2
k141_107197_5	NCBI|WP_252944138.1|1|1|almE|almE||2|COLISTIN|COLISTIN|lipid_A_modification_system_glycine--protein_ligase_AlmE|AMR|peptide	33.2	295	448	556	1.10e-39	149
k141_55427_28	SARG|gi|921979807|ref|WP_053271336.1|	30.7	202	898	648	6.40e-17	84.3
k141_55427_28	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.1	216	898	255	9.16e-17	80.1
k141_55427_28	SARG|gb|ABX00624.1|ARO:3002881|lmrC	26.6	549	898	550	3.56e-16	81.6
k141_55427_28	SARG|gi|655413091|ref|WP_028811890.1|	28.4	250	898	603	1.62e-15	79.7
k141_55427_28	SARG|gi|860594225|ref|WP_048475168.1|	27.4	259	898	620	2.92e-15	79.0
k141_55427_28	SARG|gi|496018010|ref|WP_008742581.1|	26.4	269	898	623	3.87e-15	78.6
k141_55427_28	SARG|gi|926351744|ref|WP_053683383.1|	26.2	260	898	648	9.22e-15	77.4
k141_55427_28	SARG|gi|917203192|ref|WP_051809904.1|	25.8	244	898	620	3.51e-14	75.5
k141_55427_28	SARG|gi|664100597|ref|WP_030638327.1|	25.1	263	898	601	4.47e-14	75.1
k141_55427_28	SARG|gi|503923650|ref|WP_014157644.1|	25.1	263	898	601	4.47e-14	75.1
k141_55427_39	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	24.9	261	658	1033	1.28e-09	60.5
k141_55427_39	SARG|gb|AEY83581|ARO:3000510|mupB	24.9	261	658	1033	1.28e-09	60.5
k141_55427_39	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.6	257	658	1024	1.57e-06	50.4
k141_55427_39	SARG|gb|CAA53189|ARO:3000521|mupA	22.6	257	658	1024	1.57e-06	50.4
k141_55427_39	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	21.0	262	658	1024	2.07e-06	50.1
k141_55427_39	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	21.0	262	658	1024	2.07e-06	50.1
k141_46083_10	SARG|gb|AAG06942.1|ARO:3002985|arnA	25.8	295	306	662	4.13e-27	110
k141_46083_12	SARG|CP001581.1.gene3143.p01	34.8	333	344	344	1.34e-54	181
k141_46083_12	SARG|gb|CAL84423.1|ARO:3004146|cfrC	34.5	333	344	344	1.13e-52	176
k141_46083_12	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	35.0	334	344	349	1.28e-52	176
k141_46083_12	NCBI|WP_002349981.1|1|1|cfr(B)|cfr(B)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/LINEZOLID/RETAPAMULIN/STREPTOGRAMIN_B/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(B)|AMR|multidrug	34.3	327	344	349	1.28e-52	176
k141_46083_12	SARG|gb|CDF47262.1|ARO:3004649|cfr(B)	34.3	327	344	349	1.28e-52	176
k141_46083_12	SARG|gb|AGZ55247.1|ARO:3002814|clbA	34.6	327	344	349	1.28e-52	176
k141_46083_12	SARG|gb|BAH45481.1|ARO:3002815|clbB	34.7	334	344	343	1.54e-52	176
k141_46083_12	SARG|AJ249217.gene.p01	35.0	334	344	349	3.55e-52	175
k141_46083_12	SARG|gb|AIX48090.1|ARO:3004599|clcD	33.9	327	344	349	4.98e-52	174
k141_46083_12	SARG|AXY65402.1	34.4	343	344	357	9.86e-50	169
k141_46083_14	CARD|gb|WKR28567.1|ARO:3007678|IreK	34.6	593	762	718	2.97e-76	259
k141_75984_18	SARG|gi|1001720867|ref|WP_061274204.1|	39.6	225	249	648	3.24e-41	148
k141_75984_18	SARG|gi|746253210|ref|WP_039301529.1|	39.6	225	249	648	6.15e-41	147
k141_75984_18	SARG|gi|896325272|ref|WP_049294291.1|	38.6	228	249	648	1.60e-40	146
k141_75984_18	SARG|gi|746243059|ref|WP_039291473.1|	38.7	225	249	648	2.21e-40	145
k141_75984_18	SARG|gi|639216333|ref|WP_024554080.1|	37.7	228	249	648	2.06e-39	143
k141_75984_18	SARG|gi|639225329|ref|WP_024561799.1|	37.4	246	249	648	1.90e-38	140
k141_75984_18	SARG|gi|639218559|ref|WP_024556062.1|	37.4	246	249	648	1.90e-38	140
k141_75984_18	SARG|gi|657888313|ref|WP_029592374.1|	37.0	246	249	648	2.62e-38	140
k141_55536_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	29.4	228	265	575	2.85e-24	100
k141_55536_2	SARG|gi|921979807|ref|WP_053271336.1|	30.0	230	265	648	5.16e-20	88.2
k141_55536_2	SARG|gb|AAK76136.1|ARO:3000025|patB	27.5	240	265	588	6.67e-20	87.8
k141_55536_2	SARG|gb|AAK76137.1|ARO:3000024|patA	28.0	239	265	564	3.99e-19	85.5
k141_55536_2	SARG|gb|AAC75271.1|ARO:3003952|yojI	27.8	237	265	547	6.60e-17	79.0
k141_55536_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	25.5	196	265	362	3.93e-15	73.2
k141_55536_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	24.3	247	265	664	6.43e-15	73.2
k141_55536_2	SARG|gb|ABX00624.1|ARO:3002881|lmrC	31.3	198	265	550	1.58e-13	68.9
k141_55536_2	SARG|gi|686444151|ref|WP_031925491.1|	29.6	196	265	488	3.92e-12	64.7
k141_55536_2	SARG|gi|686436876|ref|WP_031922735.1|	29.6	196	265	491	3.93e-12	64.7
k141_97121_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.9	226	232	228	1.85e-58	183
k141_97121_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.6	225	232	231	6.55e-57	179
k141_97121_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.8	222	232	219	5.19e-56	177
k141_97121_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.6	226	232	232	6.16e-55	174
k141_97121_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	39.2	232	232	233	2.08e-50	163
k141_97121_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.7	230	232	231	1.11e-49	161
k141_97121_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.4	229	232	229	6.66e-48	156
k141_97121_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.4	231	232	231	9.96e-48	156
k141_97121_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.4	231	232	231	1.41e-47	155
k141_97121_2	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.8	232	232	232	2.05e-47	155
k141_97121_3	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.6	250	478	381	2.08e-32	126
k141_97121_3	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.6	250	478	381	2.08e-32	126
k141_97121_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	31.8	258	478	370	7.73e-31	121
k141_97121_3	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.2	250	478	381	9.26e-31	121
k141_97121_3	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.2	250	478	381	9.26e-31	121
k141_97121_3	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	250	478	381	1.27e-30	121
k141_97121_3	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	250	478	381	1.27e-30	121
k141_97121_3	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	250	478	381	1.27e-30	121
k141_97121_3	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	250	478	381	1.27e-30	121
k141_97121_3	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.2	250	478	381	2.38e-30	120
k141_107701_23	SARG|gb|APB03216.1|ARO:3003982|LlmA	61.4	285	288	287	7.23e-138	389
k141_107701_24	SARG|gi|671541568|ref|WP_031525212.1|	33.6	235	285	648	6.29e-29	114
k141_107701_24	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.6	215	285	664	7.12e-18	82.4
k141_107701_24	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	25.5	208	285	528	2.48e-15	74.7
k141_107701_24	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	27.5	247	285	579	2.61e-15	74.7
k141_107701_24	SARG|gb|AAC75271.1|ARO:3003952|yojI	27.4	223	285	547	2.02e-14	72.0
k141_107701_24	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	26.4	250	285	579	2.80e-14	71.6
k141_107701_24	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	210	285	655	8.67e-10	58.2
k141_107701_24	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	26.2	221	285	552	1.08e-09	57.8
k141_107701_24	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	210	285	655	1.16e-09	57.8
k141_107701_24	SARG|gb|AKA86814|ARO:3003746|optrA	23.8	210	285	655	1.16e-09	57.8
k141_107701_25	SARG|gi|446026113|ref|WP_000103968.1|	29.6	226	290	306	8.29e-26	102
k141_107701_25	SARG|gi|500194536|ref|WP_011867743.1|	28.8	226	290	306	1.15e-25	102
k141_107701_25	SARG|gi|507044560|ref|WP_016115614.1|	29.6	226	290	306	1.15e-25	102
k141_107701_25	SARG|gi|507035724|ref|WP_016107411.1|	28.6	227	290	309	1.21e-25	102
k141_107701_25	SARG|gi|445996698|ref|WP_000074553.1|	28.6	227	290	309	1.21e-25	102
k141_107701_25	SARG|gi|445996697|ref|WP_000074552.1|	28.6	227	290	309	1.68e-25	102
k141_107701_25	SARG|gi|445996696|ref|WP_000074551.1|	28.6	227	290	309	1.68e-25	102
k141_107701_25	SARG|gi|445996719|ref|WP_000074574.1|	29.3	229	290	309	2.32e-25	101
k141_107701_25	SARG|gi|445996708|ref|WP_000074563.1|	28.5	228	290	309	2.32e-25	101
k141_107701_25	SARG|gi|445996695|ref|WP_000074550.1|	28.9	228	290	309	3.22e-25	101
k141_35684_22	SARG|gb|ABA71733.1|ARO:3002972|vanTG	41.5	342	393	712	2.32e-79	257
k141_35684_22	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	38.4	372	393	712	2.32e-70	233
k141_35684_22	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	39.2	344	393	711	6.46e-68	226
k141_35684_22	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	33.2	374	393	366	4.12e-60	197
k141_35684_22	SARG|FJ872411.1.gene43.p01	33.0	376	393	702	9.89e-54	188
k141_35684_22	SARG|gi|498467693|ref|WP_010773049.1|	32.8	378	393	700	4.87e-53	186
k141_35684_22	SARG|JF802084.2.gene3.p01	29.8	373	393	700	1.17e-50	179
k141_35684_22	megares|MEG_7535|Drugs|Glycopeptide|VanN-type_resistance_protein|VANTN_1	29.1	299	393	656	2.70e-38	144
k141_148319_1	CARD|gb|AAD51348.1|ARO:3003066|smeR	26.5	117	260	229	3.53e-06	45.8
k141_148319_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	26.7	105	260	232	3.60e-06	45.8
k141_148319_4	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	31.4	137	290	291	1.26e-08	53.9
k141_76452_8	NCBI|WP_012705551.1|1|1|blaR1_gen|blaR1_gen|regulation|2|beta-lactam|beta-lactam|BlaR1_family_beta-lactam_sensor/signal_transducer|AMR|beta-lactam	24.0	275	508	593	3.99e-16	80.1
k141_97567_13	CARD|gb|ADM92605.1|ARO:3000553|adeR	34.2	120	249	247	4.80e-11	60.1
k141_97567_13	CARD|gb|ATC67679.1|ARO:3000838|arlR	27.0	122	249	219	1.74e-08	52.4
k141_97567_13	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	25.0	120	249	228	2.56e-08	52.0
k141_97567_13	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.0	76	249	204	8.95e-06	44.3
k141_97567_18	SARG|gb|APB03219.1|ARO:3003986|TaeA	32.4	102	249	648	3.12e-09	55.8
k141_129240_9	SARG|gi|928900436|ref|WP_053931243.1|	29.0	517	603	600	3.79e-65	223
k141_129240_9	SARG|gi|664579989|ref|WP_031094015.1|	29.0	517	603	601	3.87e-65	223
k141_129240_9	SARG|gi|695865802|ref|WP_032778631.1|	28.6	518	603	605	8.07e-65	222
k141_129240_9	SARG|gi|1045390184|ref|WP_065479071.1|	28.8	518	603	605	8.07e-65	222
k141_129240_9	SARG|gi|648667297|ref|WP_026359044.1|	28.2	517	603	605	1.12e-64	222
k141_129240_9	SARG|gi|490068471|ref|WP_003970646.1|	28.6	518	603	603	2.08e-64	221
k141_129240_9	SARG|gi|497748188|ref|WP_010062372.1|	28.8	518	603	605	2.16e-64	221
k141_129240_9	SARG|gi|664180077|ref|WP_030714054.1|	28.6	518	603	605	2.16e-64	221
k141_129240_9	SARG|gi|517347347|ref|WP_018522839.1|	29.2	518	603	601	2.78e-64	221
k141_129240_9	SARG|gi|695887424|ref|WP_032788534.1|	28.6	518	603	605	3.00e-64	221
k141_129240_10	SARG|gi|501350226|ref|WP_012381861.1|	33.8	583	608	603	7.08e-85	276
k141_129240_10	SARG|gi|490068471|ref|WP_003970646.1|	33.6	583	608	603	5.32e-84	273
k141_129240_10	SARG|gi|648667297|ref|WP_026359044.1|	33.1	596	608	605	5.58e-84	273
k141_129240_10	SARG|gi|664170108|ref|WP_030704355.1|	33.5	582	608	603	7.45e-84	273
k141_129240_10	SARG|gi|928900436|ref|WP_053931243.1|	33.1	596	608	600	1.90e-83	272
k141_129240_10	SARG|gi|664579989|ref|WP_031094015.1|	33.2	594	608	601	2.72e-83	271
k141_129240_10	SARG|gi|948137056|ref|WP_056795395.1|	32.8	592	608	602	3.90e-83	271
k141_129240_10	SARG|gi|827013130|ref|WP_047175495.1|	33.2	582	608	603	1.09e-82	270
k141_129240_10	SARG|gi|951183771|ref|WP_057661487.1|	32.8	582	608	603	2.99e-82	269
k141_129240_10	SARG|gi|662754041|ref|WP_030125200.1|	33.0	594	608	601	4.00e-82	268
k141_129240_11	CARD|gb|CYF42523.1|ARO:3004047|kdpD	30.1	239	383	885	6.44e-28	114
k141_129240_11	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	26.6	233	383	357	2.10e-13	69.7
k141_129240_11	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	26.6	233	383	357	2.10e-13	69.7
k141_129240_11	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	22.3	256	383	392	6.04e-11	62.4
k141_129240_11	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	22.2	234	383	380	2.45e-10	60.5
k141_129240_11	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	22.2	234	383	380	2.45e-10	60.5
k141_129240_11	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.9	237	383	361	3.05e-10	60.1
k141_129240_11	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	24.9	237	383	361	3.05e-10	60.1
k141_129240_11	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.3	236	383	365	3.10e-10	60.1
k141_129240_11	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	25.8	233	383	361	4.07e-10	59.7
k141_129240_12	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	46.3	227	236	225	2.70e-66	203
k141_129240_12	CARD|gb|AAC73788.1|ARO:3003841|kdpE	46.3	227	236	225	2.70e-66	203
k141_129240_12	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.3	229	236	228	1.30e-42	143
k141_129240_12	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.2	224	236	219	8.04e-42	140
k141_129240_12	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.3	224	236	229	3.30e-40	137
k141_129240_12	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	31.9	226	236	232	7.88e-39	133
k141_129240_12	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	30.7	225	236	230	5.86e-38	131
k141_129240_12	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	30.5	226	236	232	8.70e-38	130
k141_129240_12	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	30.5	226	236	232	8.70e-38	130
k141_129240_12	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	31.3	227	236	231	2.37e-37	129
k141_148895_2	SARG|Q08425	26.3	456	530	641	4.08e-30	123
k141_148895_2	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.3	456	530	657	4.34e-30	123
k141_148895_2	SARG|Z21523.gene.p01	26.3	456	530	657	4.34e-30	123
k141_148895_2	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.7	456	530	654	1.04e-29	122
k141_148895_2	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	25.7	456	530	670	1.09e-29	122
k141_148895_2	SARG|AAB51122	25.7	456	530	670	1.09e-29	122
k141_148895_2	SARG|P70882	26.1	456	530	641	7.69e-29	119
k141_148895_2	SARG|BAD46890	26.1	456	530	657	8.11e-29	119
k141_148895_2	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.3	456	530	641	1.85e-28	118
k141_148895_2	SARG|AAZ79478	26.3	456	530	657	1.95e-28	118
k141_36197_5	SARG|gb|CAE00499.1|ARO:3003835|cdeA	26.9	420	458	441	1.61e-37	141
k141_36197_5	SARG|gi|446573690|ref|WP_000651036.1|	25.6	418	458	451	8.08e-35	134
k141_36197_5	SARG|gi|686396521|ref|WP_031908504.1|	26.1	417	458	451	1.11e-34	133
k141_36197_5	SARG|gi|686123390|ref|WP_031769354.1|	26.1	417	458	451	1.52e-34	133
k141_36197_5	SARG|gi|516415429|ref|WP_017804827.1|	26.1	417	458	451	1.52e-34	133
k141_36197_5	SARG|gi|446573715|ref|WP_000651061.1|	26.4	417	458	451	1.52e-34	133
k141_36197_5	SARG|gi|1006223553|ref|WP_061745579.1|	25.4	417	458	451	1.52e-34	133
k141_36197_5	SARG|gi|686367913|ref|WP_031894914.1|	26.1	417	458	451	1.52e-34	133
k141_36197_5	SARG|gi|486285962|ref|WP_001572033.1|	26.1	417	458	451	1.52e-34	133
k141_36197_5	SARG|gi|686309068|ref|WP_031870147.1|	26.1	417	458	451	1.52e-34	133
k141_47795_7	SARG|YP_523088	33.0	273	277	277	2.39e-36	129
k141_47795_7	SARG|YP_001563294	31.4	274	277	275	1.24e-35	127
k141_47795_7	SARG|YP_970399	32.2	270	277	274	4.68e-35	126
k141_47795_7	SARG|ZP_02884769	34.1	287	277	280	7.98e-34	123
k141_47795_7	SARG|YP_002552549	31.2	276	277	274	1.37e-33	122
k141_47795_7	SARG|YP_550152	31.9	276	277	277	1.46e-33	122
k141_47795_7	SARG|YP_981592	31.9	276	277	277	2.05e-33	122
k141_47795_7	SARG|YP_985461	31.5	273	277	274	3.76e-33	121
k141_47795_7	SARG|YP_997055	32.2	273	277	274	1.03e-32	120
k141_47795_7	SARG|ZP_03552050	31.5	270	277	274	1.45e-32	119
k141_149179_15	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	34.4	215	379	392	1.22e-26	108
k141_149179_15	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	28.8	215	379	364	9.28e-20	88.6
k141_149179_15	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	28.8	215	379	364	9.28e-20	88.6
k141_149179_15	CARD|gb|ADM92606.1|ARO:3000549|adeS	23.4	303	379	361	2.25e-19	87.4
k141_149179_15	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.3	209	379	364	9.67e-17	79.7
k141_149179_15	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.3	209	379	364	9.67e-17	79.7
k141_149179_16	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	37.8	201	226	233	1.73e-44	147
k141_149179_16	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	36.2	218	226	225	2.01e-34	121
k141_149179_16	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.7	220	226	219	1.05e-32	117
k141_149179_16	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.5	220	226	223	1.63e-32	116
k141_149179_16	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	220	226	219	4.11e-32	115
k141_149179_16	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	220	226	220	4.22e-32	115
k141_149179_16	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	220	226	220	5.93e-32	115
k141_149179_16	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	220	226	220	3.27e-31	113
k141_149179_16	SARG|ZP_02848503	32.3	220	226	221	1.42e-29	108
k141_149179_16	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.0	224	226	225	3.08e-29	108
k141_149179_27	SARG|gi|746609237|ref|WP_039635344.1|	36.3	240	333	322	7.58e-31	117
k141_149179_27	SARG|gi|740152780|ref|WP_037997109.1|	36.2	232	333	322	3.92e-30	115
k141_149179_27	SARG|YP_002333394	36.5	233	333	323	3.99e-30	115
k141_149179_27	SARG|FJ349556.1.gene5.p01	31.9	282	333	326	1.13e-29	114
k141_149179_27	SARG|AF155139.2.gene6.p01	35.5	245	333	322	2.80e-29	113
k141_149179_27	SARG|DQ018711.1.gene4.p01	34.5	238	333	322	2.80e-29	113
k141_149179_27	SARG|gi|737310392|ref|WP_035293250.1|	34.0	238	333	323	3.96e-29	113
k141_149179_27	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	32.0	244	333	314	6.47e-29	112
k141_149179_27	SARG|gi|738848198|ref|WP_036737307.1|	34.5	238	333	323	7.61e-29	112
k141_57298_6	SARG|gi|446048013|ref|WP_000125868.1|	28.9	311	529	648	3.03e-18	87.0
k141_57298_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.5	239	529	255	3.68e-16	77.4
k141_57298_6	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.2	245	529	664	2.87e-12	68.2
k141_57298_6	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	30.1	219	529	579	1.83e-11	65.5
k141_57298_6	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	27.8	216	529	579	3.20e-11	64.7
k141_57298_6	SARG|gi|926286457|ref|WP_053623344.1|	27.7	224	529	605	1.38e-07	53.1
k141_57298_6	SARG|gi|662175949|ref|WP_030118884.1|	26.9	223	529	605	7.27e-07	50.8
k141_57298_6	SARG|gi|663155409|ref|WP_030194633.1|	26.9	223	529	605	7.27e-07	50.8
k141_57298_6	SARG|gi|664538723|ref|WP_031054357.1|	26.9	223	529	605	7.27e-07	50.8
k141_57298_6	SARG|gi|663330365|ref|WP_030329892.1|	26.9	223	529	607	7.28e-07	50.8
k141_47827_5	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	38.3	209	610	373	1.89e-32	127
k141_47827_8	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	47.8	301	300	703	2.12e-82	261
k141_108948_5	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	39.8	374	347	703	1.10e-74	243
k141_98517_8	SARG|gi|896325272|ref|WP_049294291.1|	39.0	228	241	648	4.83e-54	182
k141_98517_8	SARG|gi|639225329|ref|WP_024561799.1|	40.0	230	241	648	6.71e-54	182
k141_98517_8	SARG|gi|639218559|ref|WP_024556062.1|	40.0	230	241	648	6.71e-54	182
k141_98517_8	SARG|gi|657888313|ref|WP_029592374.1|	40.0	230	241	648	9.33e-54	182
k141_98517_8	SARG|gi|639216333|ref|WP_024554080.1|	40.3	221	241	648	9.33e-54	182
k141_98517_8	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.8	233	241	579	9.11e-18	80.9
k141_98517_8	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	28.5	235	241	579	4.14e-17	79.0
k141_98517_8	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	28.3	233	241	578	1.55e-15	74.3
k141_98517_8	SARG|gb|WP_104671188.1|ARO:3003948|efrA	26.8	220	241	575	1.05e-13	68.9
k141_98517_8	SARG|gb|AYV52072.1|ARO:3002882|lmrD	23.0	239	241	664	3.66e-13	67.4
k141_98517_10	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.6	203	538	255	6.19e-17	79.7
k141_98517_10	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	22.1	511	538	568	3.31e-16	80.5
k141_98517_10	SARG|gi|500194536|ref|WP_011867743.1|	29.0	193	538	306	2.92e-12	66.6
k141_98517_10	SARG|gi|507050365|ref|WP_016121371.1|	28.4	194	538	309	7.21e-12	65.5
k141_98517_10	SARG|gi|488067981|ref|WP_002139378.1|	28.4	194	538	309	9.66e-12	65.1
k141_98517_10	SARG|gi|488053456|ref|WP_002124853.1|	28.4	194	538	309	9.66e-12	65.1
k141_98517_10	SARG|gi|488130770|ref|WP_002201978.1|	28.4	194	538	309	9.66e-12	65.1
k141_98517_10	SARG|gi|447195835|ref|WP_001273091.1|	28.9	194	538	306	1.26e-11	64.7
k141_98517_10	SARG|ZP_04081918	28.9	194	538	306	1.26e-11	64.7
k141_98517_10	SARG|gi|507035724|ref|WP_016107411.1|	28.9	194	538	309	1.29e-11	64.7
k141_119148_9	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.0	211	549	370	1.69e-23	101
k141_119148_9	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.9	229	549	381	2.27e-21	95.1
k141_119148_9	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.9	229	549	381	2.27e-21	95.1
k141_119148_9	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.3	216	549	365	4.61e-21	94.0
k141_119148_9	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.6	220	549	381	2.41e-20	92.0
k141_119148_9	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.6	220	549	381	2.41e-20	92.0
k141_119148_9	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.0	229	549	381	4.35e-20	91.3
k141_119148_9	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.0	229	549	381	4.35e-20	91.3
k141_119148_9	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.0	229	549	885	2.64e-15	78.2
k141_119148_10	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.9	168	173	219	2.85e-39	132
k141_119148_10	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.1	175	173	231	5.49e-36	124
k141_119148_10	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	39.6	169	173	225	1.65e-33	117
k141_119148_10	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.9	174	173	228	9.89e-33	115
k141_119148_10	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.4	177	173	232	3.05e-32	114
k141_119148_10	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.9	175	173	230	8.14e-32	113
k141_119148_10	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.8	178	173	232	8.54e-32	113
k141_119148_10	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.8	178	173	232	8.54e-32	113
k141_119148_10	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.7	175	173	231	1.66e-31	112
k141_119148_10	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.4	177	173	231	2.33e-31	112
k141_149454_15	SARG|gi|671541568|ref|WP_031525212.1|	30.7	231	509	648	2.24e-24	105
k141_6155_7	megares|MEG_727|Drugs|beta-lactam|Class_C_betalactamases|AMPC_1	33.7	403	408	415	1.83e-77	244
k141_67790_9	SARG|gi|441475675|emb|CCQ25429.1|	28.9	121	326	211	4.25e-07	48.9
k141_67790_9	SARG|HE999704.1.gene3064.p01	28.9	121	326	241	5.49e-07	48.9
k141_67790_21	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.3	227	225	231	4.96e-49	159
k141_67790_21	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.5	221	225	228	1.30e-45	150
k141_67790_21	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.9	219	225	219	4.52e-44	146
k141_67790_21	CARD|gb|AAD51348.1|ARO:3003066|smeR	38.1	223	225	229	5.98e-44	146
k141_67790_21	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.0	226	225	232	6.49e-44	146
k141_67790_21	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	37.6	234	225	252	2.48e-42	142
k141_67790_21	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	226	225	231	4.42e-41	139
k141_67790_21	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	226	225	231	6.24e-41	138
k141_67790_21	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	226	225	231	8.81e-41	138
k141_67790_21	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	226	225	231	1.24e-40	137
k141_36653_2	SARG|AAD41881	36.7	316	345	323	1.45e-62	201
k141_36653_2	SARG|AAR37059	39.9	283	345	323	1.61e-61	198
k141_36653_2	SARG|AAD51059	36.4	316	345	323	6.34e-61	197
k141_36653_2	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	38.4	292	345	323	3.53e-60	195
k141_36653_2	SARG|gb|AAB05626.1|ARO:3002943|vanHB	39.6	283	345	323	1.96e-59	193
k141_36653_2	SARG|KF478993.1.gene2.p01	38.4	289	345	350	2.06e-59	194
k141_36653_2	SARG|DQ018711.1.gene4.p01	37.9	285	345	322	2.69e-59	192
k141_36653_2	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	38.9	288	345	351	2.97e-59	193
k141_36653_2	SARG|AAD42183	36.4	316	345	322	3.78e-59	192
k141_36653_2	SARG|Q47748	39.6	283	345	323	3.89e-59	192
k141_140120_4	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	29.8	830	936	1033	3.84e-108	357
k141_140120_4	SARG|gb|AEY83581|ARO:3000510|mupB	29.8	830	936	1033	3.84e-108	357
k141_140120_4	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	29.0	766	936	1024	4.28e-105	349
k141_140120_4	SARG|gb|CAA53189|ARO:3000521|mupA	29.0	766	936	1024	4.28e-105	349
k141_140120_4	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	29.0	766	936	1024	5.93e-105	348
k141_140120_4	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	29.0	766	936	1024	5.93e-105	348
k141_140120_4	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	28.4	824	936	1107	6.87e-84	291
k141_140120_4	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	28.4	824	936	1107	6.87e-84	291
k141_6290_20	SARG|L42544.gene.p01	31.4	634	853	651	1.58e-90	298
k141_6290_20	SARG|AAV80410	31.4	634	853	651	1.58e-90	298
k141_6290_20	SARG|YP_002850805	31.7	649	853	652	1.67e-86	288
k141_6290_20	SARG|ZP_02952732	32.2	649	853	652	6.22e-86	286
k141_6290_20	SARG|ZP_02632674	32.2	649	853	660	7.48e-86	286
k141_6290_20	SARG|L20800.gene.p01	32.0	649	853	652	2.32e-85	285
k141_6290_20	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	30.4	615	853	654	4.68e-85	284
k141_6290_20	SARG|Q08425	30.2	615	853	641	6.68e-85	283
k141_6290_20	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	30.4	615	853	670	6.75e-85	284
k141_6290_20	SARG|AAB51122	30.4	615	853	670	6.75e-85	284
k141_6290_37	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	29.5	217	235	293	7.37e-32	117
k141_6290_37	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	24.9	209	235	293	1.91e-15	72.8
k141_6290_37	SARG|gi|736472622|ref|WP_034494292.1|	24.1	199	235	648	7.09e-11	60.5
k141_6290_37	SARG|gi|1035670474|ref|WP_064517458.1|	23.6	199	235	648	2.33e-10	58.9
k141_6290_37	SARG|gi|1035717981|ref|WP_064557480.1|	23.6	199	235	648	2.33e-10	58.9
k141_6290_37	SARG|gi|1035706844|ref|WP_064548272.1|	23.1	199	235	648	5.70e-10	57.8
k141_6290_37	SARG|gi|803568669|ref|WP_046077412.1|	23.3	232	235	648	8.74e-08	51.2
k141_6290_37	SARG|gi|446110352|ref|WP_000188207.1|	23.3	232	235	648	8.74e-08	51.2
k141_6290_37	SARG|YP_002382193	23.3	232	235	648	8.74e-08	51.2
k141_6290_37	SARG|gi|803575554|ref|WP_046081557.1|	23.3	232	235	648	8.74e-08	51.2
k141_130446_7	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	26.1	785	883	1033	6.89e-83	286
k141_130446_7	SARG|gb|AEY83581|ARO:3000510|mupB	26.1	785	883	1033	6.89e-83	286
k141_130446_7	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	26.4	814	883	1024	1.31e-80	280
k141_130446_7	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	26.4	814	883	1024	1.31e-80	280
k141_130446_7	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	26.4	814	883	1024	4.60e-80	278
k141_130446_7	SARG|gb|CAA53189|ARO:3000521|mupA	26.4	814	883	1024	4.60e-80	278
k141_6570_7	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.8	226	251	307	3.08e-13	67.0
k141_6570_7	SARG|gi|912614197|ref|WP_050196089.1|	25.0	228	251	648	1.24e-10	60.1
k141_6570_7	SARG|gb|QHW12375.1|ARO:3005087|msrF	25.6	199	251	486	3.03e-08	52.8
k141_6570_7	SARG|gb|QNR09092.1|ARO:3007042|msr(G)	27.1	199	251	485	4.07e-08	52.4
k141_6570_7	SARG|U82085.gene.p01	27.5	207	251	552	7.69e-08	51.6
k141_6570_7	SARG|QHW12308.1	25.6	199	251	486	2.36e-07	50.1
k141_6570_7	SARG|DAC81085.1	25.0	196	251	486	7.59e-07	48.5
k141_6570_7	SARG|gb|QQA64075.1|ARO:3007043|msr(I)	25.4	193	251	485	1.82e-06	47.4
k141_6570_33	SARG|Q83LR7	32.8	238	336	648	2.34e-24	102
k141_6570_33	SARG|gi|647325472|ref|WP_025760953.1|	32.8	238	336	648	2.34e-24	102
k141_6570_33	SARG|gi|647323678|ref|WP_025760497.1|	32.8	238	336	648	2.34e-24	102
k141_6570_33	SARG|gi|446110305|ref|WP_000188160.1|	33.2	238	336	648	5.76e-24	101
k141_6570_33	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.8	211	336	255	7.55e-24	97.4
k141_6570_33	SARG|gi|751930065|ref|WP_041144773.1|	32.2	230	336	648	1.91e-23	100
k141_6570_33	SARG|gi|495067432|ref|WP_007792257.1|	33.0	230	336	647	4.68e-23	99.0
k141_6570_33	SARG|gi|494938585|ref|WP_007664615.1|	33.2	238	336	647	4.68e-23	99.0
k141_6570_33	SARG|gi|506220920|ref|WP_015740695.1|	33.5	230	336	647	6.31e-23	98.6
k141_6570_33	SARG|gi|446110307|ref|WP_000188162.1|	32.8	238	336	648	6.31e-23	98.6
k141_6570_34	SARG|gb|ADZ12699.1|ARO:3005091|RanA	29.3	229	320	258	4.46e-27	105
k141_6570_34	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	29.1	234	320	574	1.00e-15	76.6
k141_6570_34	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	26.7	236	320	550	1.54e-08	54.7
k141_6570_34	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	25.8	186	320	505	1.96e-08	54.3
k141_6570_34	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	22.8	184	320	504	6.07e-07	49.7
k141_6570_34	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.5	188	320	552	2.62e-06	47.8
k141_88412_5	SARG|gi|1035706844|ref|WP_064548272.1|	28.6	126	942	648	2.45e-07	53.5
k141_109518_1	SARG|gi|504542119|ref|WP_014729221.1|	36.2	185	185	647	7.72e-22	90.9
k141_109518_1	SARG|gi|506220920|ref|WP_015740695.1|	35.7	185	185	647	1.05e-21	90.5
k141_109518_1	SARG|gi|696402390|ref|WP_032974230.1|	35.7	185	185	647	1.43e-21	90.1
k141_109518_1	SARG|gi|696423952|ref|WP_032993748.1|	35.7	185	185	647	1.43e-21	90.1
k141_109518_1	SARG|YP_001438541	35.7	185	185	647	3.60e-21	89.0
k141_109518_1	SARG|gi|938461734|ref|WP_054625806.1|	35.7	185	185	647	3.60e-21	89.0
k141_109518_1	SARG|gi|938460528|ref|WP_054624864.1|	35.7	185	185	647	3.60e-21	89.0
k141_109518_1	SARG|gi|490522515|ref|WP_004387938.1|	35.7	185	185	647	3.60e-21	89.0
k141_109518_1	SARG|gi|742378414|ref|WP_038857601.1|	35.7	185	185	647	3.60e-21	89.0
k141_109518_1	SARG|gi|1020141879|ref|WP_063264839.1|	35.7	185	185	647	4.90e-21	88.6
k141_78153_3	SARG|gi|752682279|ref|WP_041330231.1|	39.3	354	362	349	2.52e-84	258
k141_78153_3	SARG|gi|985522334|ref|WP_060811963.1|	42.7	361	362	342	4.07e-84	258
k141_78153_3	SARG|gb|KTE89608.1|ARO:3003723|vanI	43.2	361	362	348	4.89e-84	258
k141_78153_3	SARG|gi|1028100561|ref|WP_063856696.1|	39.3	354	362	349	7.13e-84	257
k141_78153_3	SARG|gi|498515088|ref|WP_010815295.1|	42.4	361	362	342	1.15e-83	256
k141_78153_3	SARG|Q06893	42.4	361	362	342	4.59e-83	255
k141_78153_3	SARG|gi|1028848468|ref|WP_064017431.1|	41.6	363	362	343	9.46e-83	254
k141_78153_3	SARG|gi|498515253|ref|WP_010815429.1|	42.1	361	362	342	1.30e-82	254
k141_78153_3	SARG|gi|405945042|pdb|4FU0|A	38.8	356	362	357	1.45e-82	254
k141_78153_3	SARG|DQ212986.1.gene8.p01	38.7	354	362	349	1.60e-82	254
k141_99716_1	SARG|gi|926400371|ref|WP_053728483.1|	25.0	240	340	603	8.14e-10	58.9
k141_99716_1	SARG|gi|493394434|ref|WP_006350564.1|	25.8	209	340	602	3.39e-09	57.0
k141_99716_1	SARG|gi|655401130|ref|WP_028800283.1|	25.3	257	340	599	5.99e-09	56.2
k141_99716_1	SARG|gi|944152509|ref|WP_055644808.1|	24.3	214	340	616	6.07e-09	56.2
k141_99716_1	SARG|gi|739906046|ref|WP_037756452.1|	24.6	228	340	620	6.08e-09	56.2
k141_99716_1	SARG|gi|516574297|ref|WP_017949361.1|	24.3	226	340	620	6.08e-09	56.2
k141_99716_1	SARG|gi|926351744|ref|WP_053683383.1|	24.6	228	340	648	8.24e-09	55.8
k141_99716_1	SARG|gi|1033217078|gb|OAR27197.1|	25.0	228	340	601	1.41e-08	55.1
k141_99716_1	SARG|gi|516795764|ref|WP_018105258.1|	25.1	211	340	601	1.41e-08	55.1
k141_99716_1	SARG|gi|663330365|ref|WP_030329892.1|	24.7	243	340	607	1.42e-08	55.1
k141_99716_12	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.7	259	265	255	1.26e-27	105
k141_99716_12	SARG|gb|AAV85982.1|ARO:3000535|macB	32.1	234	265	644	4.84e-23	97.1
k141_99716_12	SARG|gi|742378414|ref|WP_038857601.1|	28.5	263	265	647	2.60e-18	83.2
k141_99716_12	SARG|gi|498115003|ref|WP_010429159.1|	28.1	256	265	646	3.52e-18	82.8
k141_99716_12	SARG|gi|696411918|ref|WP_032982657.1|	29.5	237	265	647	6.43e-18	82.0
k141_99716_12	SARG|gi|1017024088|ref|WP_063159864.1|	27.7	256	265	646	8.68e-18	81.6
k141_99716_12	SARG|gi|754493745|ref|WP_041910640.1|	28.1	256	265	646	8.68e-18	81.6
k141_99716_12	SARG|gi|695720417|ref|WP_032647870.1|	27.7	256	265	646	8.68e-18	81.6
k141_99716_12	SARG|gi|983405167|ref|WP_060572706.1|	28.1	256	265	646	8.68e-18	81.6
k141_99716_12	SARG|gi|696402390|ref|WP_032974230.1|	29.5	237	265	647	8.69e-18	81.6
k141_159312_3	SARG|gb|AAK76136.1|ARO:3000025|patB	32.9	601	626	588	8.28e-95	302
k141_159312_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.8	546	626	664	1.28e-90	293
k141_159312_3	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.3	610	626	579	5.88e-86	278
k141_159312_3	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.2	609	626	579	3.68e-82	268
k141_159312_3	SARG|gi|664556405|ref|WP_031071225.1|	32.6	605	626	602	6.38e-82	268
k141_159312_3	SARG|gi|860594225|ref|WP_048475168.1|	31.9	599	626	620	3.84e-80	264
k141_159312_3	SARG|AF170880.4.gene1.p01	30.5	597	626	615	6.68e-80	263
k141_159312_3	SARG|gi|948137056|ref|WP_056795395.1|	30.5	620	626	602	9.67e-80	263
k141_159312_3	SARG|gi|1033217078|gb|OAR27197.1|	30.9	598	626	601	1.32e-79	262
k141_159312_3	SARG|gi|558888514|ref|WP_023543283.1|	30.3	597	626	615	2.54e-79	262
k141_159312_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.4	546	583	575	7.99e-113	347
k141_159312_4	SARG|gb|AAK76137.1|ARO:3000024|patA	36.9	531	583	564	1.26e-100	315
k141_159312_4	SARG|gi|739906046|ref|WP_037756452.1|	31.5	536	583	620	1.29e-70	238
k141_159312_4	SARG|gi|1045390184|ref|WP_065479071.1|	29.5	567	583	605	1.87e-69	234
k141_159312_4	SARG|gi|928900436|ref|WP_053931243.1|	30.0	574	583	600	2.35e-69	234
k141_159312_4	SARG|gi|664579989|ref|WP_031094015.1|	30.0	574	583	601	2.40e-69	234
k141_159312_4	SARG|gi|516574297|ref|WP_017949361.1|	31.3	536	583	620	2.54e-69	234
k141_159312_4	SARG|gi|664556405|ref|WP_031071225.1|	29.6	574	583	602	4.76e-69	233
k141_159312_4	SARG|gi|664042835|ref|WP_030582300.1|	29.6	574	583	604	6.91e-69	233
k141_159312_4	SARG|gi|1011069317|ref|WP_062010695.1|	30.4	585	583	614	8.47e-69	233
k141_49428_3	SARG|gi|671541568|ref|WP_031525212.1|	29.7	202	505	648	4.94e-20	92.4
k141_49428_3	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	25.4	244	505	293	3.57e-07	50.8
k141_37798_7	SARG|gi|976150171|ref|WP_059308384.1|	50.5	216	240	646	2.61e-70	226
k141_37798_7	SARG|gi|779958642|ref|WP_045406003.1|	50.9	216	240	646	2.61e-70	226
k141_37798_7	SARG|gi|749017716|ref|WP_040076354.1|	50.5	216	240	646	3.66e-70	225
k141_37798_7	SARG|gi|498115003|ref|WP_010429159.1|	50.5	216	240	646	3.66e-70	225
k141_37798_7	SARG|gi|493862656|ref|WP_006809409.1|	50.9	216	240	646	5.13e-70	225
k141_37798_7	SARG|gi|1028112073|ref|WP_063866263.1|	50.9	216	240	646	5.13e-70	225
k141_37798_7	SARG|gi|992390012|ref|WP_061077002.1|	49.3	227	240	648	7.45e-70	224
k141_37798_7	SARG|gi|695748190|ref|WP_032674455.1|	50.5	216	240	646	1.01e-69	224
k141_37798_7	SARG|gi|544824889|ref|WP_021240890.1|	50.5	216	240	646	1.01e-69	224
k141_37798_7	SARG|gi|974588181|ref|WP_059178476.1|	50.0	216	240	646	1.01e-69	224
k141_37798_8	SARG|gi|919893883|ref|WP_052903625.1|	32.9	431	427	648	8.45e-46	166
k141_37798_8	SARG|gi|1035686596|ref|WP_064530178.1|	32.9	431	427	648	1.16e-45	166
k141_37798_8	SARG|gi|693137385|ref|WP_032279889.1|	32.9	431	427	648	1.60e-45	166
k141_37798_8	SARG|gi|896325272|ref|WP_049294291.1|	34.1	431	427	648	1.60e-45	166
k141_37798_8	SARG|gi|639216333|ref|WP_024554080.1|	34.1	431	427	648	1.60e-45	166
k141_37798_8	SARG|gi|693238509|ref|WP_032348033.1|	32.9	431	427	648	2.20e-45	165
k141_37798_8	SARG|gi|693158925|ref|WP_032294786.1|	32.9	431	427	648	2.20e-45	165
k141_37798_8	SARG|gi|979540828|ref|WP_059340323.1|	32.9	431	427	648	2.20e-45	165
k141_37798_8	SARG|gi|693154645|ref|WP_032291313.1|	32.9	431	427	648	2.20e-45	165
k141_37798_8	SARG|gi|446110322|ref|WP_000188177.1|	32.9	431	427	648	3.02e-45	165
k141_37798_19	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	36.4	517	549	533	4.34e-88	280
k141_37798_19	SARG|AF353562.gene.p01	34.0	379	549	369	6.41e-49	172
k141_78876_1	NCBI|WP_000369214.1|1|1|mecI_of_mecA|mecI_of_mecA||2|METHICILLIN|beta-lactam|mecA-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	39.1	46	57	123	3.97e-06	39.7
k141_78876_1	NCBI|WP_000369216.1|1|1|mecI_of_mecA|mecI_of_mecA||2|METHICILLIN|beta-lactam|mecA-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	39.1	46	57	123	3.97e-06	39.7
k141_131992_6	SARG|gi|926294973|ref|WP_053631154.1|	25.4	492	581	620	2.10e-33	134
k141_131992_6	SARG|gi|921231571|ref|WP_053176464.1|	23.9	545	581	620	2.83e-33	133
k141_131992_6	SARG|gi|926356413|ref|WP_053687351.1|	25.4	492	581	620	2.83e-33	133
k141_131992_6	SARG|gi|772774655|ref|WP_045322518.1|	26.0	492	581	620	2.83e-33	133
k141_131992_6	SARG|gi|917172177|ref|WP_051778889.1|	23.9	545	581	620	3.81e-33	133
k141_131992_6	SARG|gi|919568551|ref|WP_052871170.1|	23.5	541	581	620	6.89e-33	132
k141_131992_6	SARG|gi|799286378|ref|WP_045936958.1|	25.2	492	581	620	9.26e-33	132
k141_131992_6	SARG|gi|917127754|ref|WP_051734466.1|	25.2	492	581	620	9.26e-33	132
k141_131992_6	SARG|gi|926345639|ref|WP_053677539.1|	25.2	492	581	620	1.25e-32	131
k141_131992_6	SARG|gi|926376632|ref|WP_053705806.1|	25.2	492	581	620	1.67e-32	131
k141_131992_7	SARG|gi|860594225|ref|WP_048475168.1|	29.9	525	554	620	8.39e-46	169
k141_131992_7	SARG|gi|926400371|ref|WP_053728483.1|	30.9	531	554	603	5.58e-44	164
k141_131992_7	SARG|AF170880.4.gene1.p01	29.7	532	554	615	8.78e-44	163
k141_131992_7	SARG|gi|558888514|ref|WP_023543283.1|	29.2	531	554	615	1.20e-43	163
k141_131992_7	SARG|gi|496018010|ref|WP_008742581.1|	29.6	531	554	623	1.79e-43	162
k141_131992_7	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.6	521	554	579	2.73e-43	161
k141_131992_7	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.0	521	554	579	7.02e-43	160
k141_131992_7	SARG|gi|663350985|ref|WP_030349761.1|	29.3	461	554	613	4.96e-42	158
k141_131992_7	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	22.9	424	554	574	1.32e-19	91.3
k141_131992_7	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	29.9	174	554	528	5.41e-15	76.6
k141_18236_3	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.4	312	458	451	1.11e-34	133
k141_18236_3	CARD|gb|AEX49906.1|ARO:3003583|basS	29.7	239	458	477	9.96e-24	102
k141_18236_3	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	30.8	221	458	447	2.15e-22	98.2
k141_18236_3	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	30.8	221	458	447	2.15e-22	98.2
k141_18236_3	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	30.8	221	458	447	2.15e-22	98.2
k141_18236_3	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	30.8	221	458	447	3.90e-22	97.4
k141_18236_3	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	31.7	202	458	454	5.50e-22	97.1
k141_18236_3	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.3	251	458	382	1.29e-18	86.3
k141_18236_3	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	26.3	251	458	382	1.29e-18	86.3
k141_18236_3	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.0	254	458	386	7.82e-18	84.0
k141_18236_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.0	224	229	231	1.68e-56	178
k141_18236_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	41.3	223	229	228	3.07e-56	177
k141_18236_4	CARD|gb|ATC67679.1|ARO:3000838|arlR	44.2	226	229	219	2.66e-55	175
k141_18236_4	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.4	227	229	232	2.53e-53	170
k141_18236_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.3	225	229	232	1.01e-52	169
k141_18236_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.3	225	229	232	1.01e-52	169
k141_18236_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.0	223	229	229	5.24e-52	167
k141_18236_4	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	41.7	228	229	235	2.50e-51	165
k141_18236_4	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.0	226	229	232	5.17e-50	162
k141_18236_4	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.3	227	229	232	1.03e-49	161
k141_120621_4	SARG|gi|500465078|gb|EOP76697.1|	34.7	219	296	306	4.08e-35	127
k141_120621_4	SARG|gi|500448961|gb|EOP61695.1|	34.7	219	296	306	5.70e-35	127
k141_120621_4	SARG|P42332	33.3	219	296	306	2.18e-34	125
k141_120621_4	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	33.3	219	296	306	2.18e-34	125
k141_120621_4	SARG|gi|510143239|gb|AGN36970.1|	33.3	219	296	313	2.52e-34	125
k141_120621_4	SARG|ABB80128	33.3	219	296	306	4.26e-34	125
k141_120621_4	SARG|ZP_04081918	32.0	219	296	306	1.16e-33	124
k141_120621_4	SARG|AAD21213	32.9	219	296	306	1.62e-33	123
k141_120621_4	SARG|gi|447195835|ref|WP_001273091.1|	32.0	219	296	306	3.17e-33	122
k141_120621_4	SARG|gi|446026113|ref|WP_000103968.1|	31.1	219	296	306	3.17e-33	122
k141_132278_1	SARG|KF478993.1.gene2.p01	38.2	178	224	350	2.53e-19	84.0
k141_132278_1	SARG|Q47748	35.6	177	224	323	2.37e-17	78.2
k141_132278_1	SARG|gi|985522333|ref|WP_060811962.1|	35.6	177	224	323	2.37e-17	78.2
k141_132278_1	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	34.4	180	224	337	2.66e-17	78.2
k141_132278_1	SARG|gi|498515089|ref|WP_010815296.1|	35.6	177	224	323	3.25e-17	77.8
k141_132278_1	SARG|gb|AAB05626.1|ARO:3002943|vanHB	35.8	176	224	323	3.25e-17	77.8
k141_132278_1	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	32.8	177	224	323	5.06e-15	71.6
k141_132278_1	SARG|AF310956.2.gene5.p01	32.8	177	224	323	6.92e-15	71.2
k141_132278_1	SARG|YP_002333394	32.8	177	224	323	6.92e-15	71.2
k141_132278_1	SARG|AAF72362	30.9	178	224	323	3.41e-12	63.5
k141_132278_4	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	29.0	162	253	461	1.32e-07	50.8
k141_132278_4	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	27.8	162	253	461	5.82e-06	45.8
k141_132278_4	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.3	215	253	552	8.31e-06	45.4
k141_27972_8	SARG|gi|447057509|ref|WP_001134765.1|	28.9	232	504	309	1.83e-14	73.2
k141_27972_8	SARG|gi|507023808|ref|WP_016095885.1|	28.0	232	504	309	3.30e-14	72.4
k141_27972_8	SARG|ZP_04081918	28.0	250	504	306	4.30e-14	72.0
k141_27972_8	SARG|gi|488068784|ref|WP_002140181.1|	28.0	232	504	309	5.95e-14	71.6
k141_27972_8	SARG|gi|447057510|ref|WP_001134766.1|	28.0	232	504	309	5.95e-14	71.6
k141_27972_8	SARG|gi|447195835|ref|WP_001273091.1|	27.6	250	504	306	1.04e-13	70.9
k141_27972_8	SARG|gi|447195836|ref|WP_001273092.1|	27.6	250	504	306	1.04e-13	70.9
k141_27972_8	SARG|gi|488120365|ref|WP_002191762.1|	27.6	232	504	309	1.07e-13	70.9
k141_27972_8	SARG|gi|445996719|ref|WP_000074574.1|	28.4	232	504	309	1.44e-13	70.5
k141_27972_8	SARG|gi|488067981|ref|WP_002139378.1|	28.0	232	504	309	1.44e-13	70.5
k141_151416_3	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	47.5	221	225	223	3.21e-74	223
k141_151416_3	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	29.6	226	225	231	8.86e-30	109
k141_151416_3	CARD|gb|AAD51348.1|ARO:3003066|smeR	30.0	220	225	229	1.67e-29	108
k141_151416_3	CARD|gb|AAG05188.1|ARO:3005068|ParR	30.0	220	225	235	1.47e-28	106
k141_151416_3	CARD|gb|ADM92605.1|ARO:3000553|adeR	29.5	220	225	247	7.40e-28	105
k141_151416_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	28.0	225	225	233	2.24e-26	100
k141_151416_3	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	27.2	206	225	225	1.72e-21	87.8
k141_151416_3	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	29.7	222	225	233	7.84e-18	78.2
k141_151416_3	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	25.7	230	225	252	1.46e-17	77.8
k141_151416_4	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	32.1	330	330	341	4.87e-49	166
k141_151416_5	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	46.0	252	255	255	1.01e-80	242
k141_151416_5	SARG|YP_001571041	39.7	234	255	648	1.07e-54	185
k141_151416_5	SARG|gi|960873409|ref|WP_058345546.1|	40.4	223	255	648	5.57e-54	183
k141_151416_5	SARG|gi|545248218|ref|WP_021546584.1|	40.5	222	255	648	1.08e-53	182
k141_151416_5	SARG|gi|740610794|ref|WP_038396317.1|	39.9	223	255	648	2.08e-53	181
k141_151416_5	SARG|gi|502669352|ref|WP_012905216.1|	40.3	221	255	648	2.89e-53	181
k141_151416_5	SARG|gi|835330218|ref|WP_047457825.1|	38.2	249	255	648	4.02e-53	181
k141_151416_5	SARG|YP_001453760	38.2	249	255	648	4.02e-53	181
k141_151416_5	SARG|gi|555268037|ref|WP_023249477.1|	39.3	234	255	648	5.58e-53	180
k141_151416_5	SARG|gi|924626178|ref|WP_053530123.1|	39.3	234	255	648	7.76e-53	180
k141_151416_6	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	25.7	690	688	641	4.00e-42	161
k141_18866_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	33.8	562	582	575	3.26e-104	325
k141_18866_4	SARG|gb|AAK76137.1|ARO:3000024|patA	35.1	569	582	564	1.03e-102	320
k141_18866_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.5	498	582	582	1.61e-68	231
k141_18866_4	SARG|gi|926400371|ref|WP_053728483.1|	29.0	572	582	603	3.46e-68	231
k141_18866_4	SARG|gi|919568551|ref|WP_052871170.1|	29.6	567	582	620	1.31e-67	229
k141_18866_4	SARG|gi|943896259|ref|WP_055534530.1|	29.1	567	582	601	1.74e-67	229
k141_18866_4	SARG|AF170880.4.gene1.p01	29.3	573	582	615	2.30e-67	229
k141_18866_4	SARG|gi|664556405|ref|WP_031071225.1|	29.2	569	582	602	2.47e-67	228
k141_18866_4	SARG|gi|926351744|ref|WP_053683383.1|	32.8	481	582	648	4.33e-67	229
k141_18866_4	SARG|gi|944470764|ref|WP_055701183.1|	29.5	567	582	601	4.68e-67	228
k141_18866_5	SARG|gb|AAK76136.1|ARO:3000025|patB	32.8	625	652	588	5.13e-92	295
k141_18866_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.7	568	652	664	5.56e-87	284
k141_18866_5	SARG|gi|517381192|ref|WP_018555350.1|	29.8	625	652	602	3.68e-77	256
k141_18866_5	SARG|gi|497748188|ref|WP_010062372.1|	29.0	621	652	605	1.07e-76	255
k141_18866_5	SARG|gi|695887424|ref|WP_032788534.1|	28.8	621	652	605	1.09e-75	253
k141_18866_5	SARG|gi|928900436|ref|WP_053931243.1|	28.9	623	652	600	1.90e-75	252
k141_18866_5	SARG|gi|558888514|ref|WP_023543283.1|	28.7	623	652	615	1.90e-75	252
k141_18866_5	SARG|gi|664579989|ref|WP_031094015.1|	28.9	623	652	601	1.94e-75	252
k141_18866_5	SARG|gi|764446018|ref|WP_044369325.1|	28.7	621	652	605	4.12e-75	251
k141_18866_5	SARG|gi|695865802|ref|WP_032778631.1|	28.7	621	652	605	8.00e-75	250
k141_90556_4	SARG|gb|BAE85481.1|ARO:3003727|vanKI	35.8	371	355	375	5.03e-67	214
k141_90556_4	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_3	34.2	363	355	409	9.76e-62	202
k141_90556_5	SARG|gb|ABA71733.1|ARO:3002972|vanTG	29.8	349	364	712	5.62e-35	134
k141_90556_5	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	26.4	349	364	711	1.08e-22	98.6
k141_121678_3	SARG|gi|488374619|ref|WP_002444004.1|	25.6	449	458	452	2.03e-38	144
k141_121678_3	SARG|gi|505177635|ref|WP_015364737.1|	26.2	404	458	451	1.29e-36	139
k141_121678_3	SARG|ZP_04679156	26.2	404	458	451	1.20e-35	136
k141_121678_3	SARG|gi|1006223553|ref|WP_061745579.1|	24.9	450	458	451	2.13e-31	124
k141_121678_3	SARG|gi|686432388|ref|WP_031921070.1|	24.3	411	458	451	6.57e-30	120
k141_121678_3	SARG|gi|565830932|ref|WP_023914633.1|	24.8	415	458	451	8.96e-30	119
k141_121678_3	SARG|gi|446573707|ref|WP_000651053.1|	24.8	415	458	451	8.96e-30	119
k141_121678_3	SARG|gi|446573715|ref|WP_000651061.1|	24.8	415	458	451	8.96e-30	119
k141_121678_3	SARG|ZP_03986195	24.3	411	458	451	1.22e-29	119
k141_121678_3	SARG|gi|446573690|ref|WP_000651036.1|	24.5	417	458	451	2.27e-29	118
k141_39692_11	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	31.4	242	727	365	3.98e-26	109
k141_39692_11	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.7	263	727	370	1.05e-25	108
k141_39692_11	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.8	225	727	367	4.82e-24	103
k141_39692_11	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.8	225	727	368	4.89e-24	103
k141_39692_11	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	26.2	244	727	380	1.89e-23	102
k141_39692_11	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.2	244	727	380	1.89e-23	102
k141_39692_11	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.3	244	727	381	3.86e-21	95.1
k141_39692_11	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.3	244	727	381	3.86e-21	95.1
k141_39692_11	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.8	212	727	364	1.37e-20	93.2
k141_39692_11	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.8	212	727	364	1.37e-20	93.2
k141_39692_12	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.7	228	232	232	8.95e-68	207
k141_39692_12	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.7	228	232	232	8.95e-68	207
k141_39692_12	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.9	231	232	235	3.96e-67	206
k141_39692_12	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	43.7	231	232	239	9.00e-67	205
k141_39692_12	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.2	225	232	231	1.41e-66	204
k141_39692_12	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	42.8	229	232	233	1.71e-65	201
k141_39692_12	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	43.0	228	232	229	4.30e-65	200
k141_39692_12	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.4	224	232	232	1.53e-63	196
k141_39692_12	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.9	227	232	231	6.84e-62	192
k141_39692_12	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.9	227	232	231	6.84e-62	192
k141_60198_7	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.3	225	229	231	8.89e-51	164
k141_60198_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.9	230	229	232	1.29e-50	163
k141_60198_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.9	230	229	232	1.29e-50	163
k141_60198_7	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.1	227	229	229	1.07e-48	158
k141_60198_7	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	37.5	232	229	239	2.84e-48	157
k141_60198_7	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.2	231	229	235	3.58e-48	157
k141_60198_7	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.6	229	229	231	1.28e-47	155
k141_60198_7	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.6	229	229	231	2.55e-47	155
k141_60198_7	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.6	229	229	231	3.60e-47	154
k141_60198_7	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.6	229	229	233	3.81e-47	154
k141_29201_11	SARG|gb|CAE00499.1|ARO:3003835|cdeA	20.5	430	446	441	7.33e-19	87.4
k141_29266_2	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	37.1	221	237	293	3.67e-42	144
k141_29266_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	33.5	221	237	307	3.60e-38	134
k141_161913_3	SARG|gi|740152780|ref|WP_037997109.1|	36.6	265	327	322	3.06e-43	150
k141_161913_3	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	35.5	245	327	314	5.95e-40	141
k141_161913_3	SARG|gi|749574782|ref|WP_040203616.1|	35.4	246	327	323	7.31e-40	141
k141_161913_3	SARG|YP_002333394	38.2	238	327	323	1.02e-39	141
k141_161913_3	SARG|AF310956.2.gene5.p01	38.2	238	327	323	1.43e-39	140
k141_161913_3	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	38.2	238	327	323	1.43e-39	140
k141_161913_3	SARG|gi|498515089|ref|WP_010815296.1|	37.6	237	327	323	2.80e-39	140
k141_161913_3	SARG|gi|985522333|ref|WP_060811962.1|	37.6	237	327	323	3.92e-39	139
k141_161913_3	SARG|gi|737310392|ref|WP_035293250.1|	36.6	232	327	323	5.48e-39	139
k141_161913_3	SARG|AAY52004	33.6	274	327	322	7.50e-39	139
k141_40076_2	SARG|gi|507044560|ref|WP_016115614.1|	34.7	72	281	306	3.24e-11	61.6
k141_40076_2	SARG|gi|446026113|ref|WP_000103968.1|	34.7	72	281	306	5.91e-11	60.8
k141_40076_2	SARG|gi|445996719|ref|WP_000074574.1|	36.2	69	281	309	2.68e-10	58.9
k141_40076_2	SARG|gi|445996710|ref|WP_000074565.1|	36.2	69	281	309	4.85e-10	58.2
k141_40076_2	SARG|gi|488068784|ref|WP_002140181.1|	33.3	78	281	309	6.54e-10	57.8
k141_40076_2	SARG|gi|488067981|ref|WP_002139378.1|	32.1	78	281	309	8.80e-10	57.4
k141_40076_2	SARG|gi|507023808|ref|WP_016095885.1|	32.1	78	281	309	8.80e-10	57.4
k141_40076_2	SARG|gi|447057509|ref|WP_001134765.1|	32.1	78	281	309	8.80e-10	57.4
k141_40076_2	SARG|gi|487936534|ref|WP_002010000.1|	32.1	78	281	309	8.80e-10	57.4
k141_40076_2	SARG|gi|445996724|ref|WP_000074579.1|	34.8	69	281	309	1.18e-09	57.0
k141_40076_3	SARG|gb|AAA26793|ARO:3003748|oleC	30.5	220	238	325	2.20e-21	89.7
k141_40076_3	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	30.7	218	238	325	3.03e-21	89.4
k141_40076_3	SARG|gi|1035717981|ref|WP_064557480.1|	24.7	247	238	648	8.89e-18	80.9
k141_40076_3	SARG|gi|1035670474|ref|WP_064517458.1|	24.7	247	238	648	1.63e-17	80.1
k141_40076_3	SARG|gi|736472622|ref|WP_034494292.1|	23.9	247	238	648	1.63e-17	80.1
k141_40076_3	SARG|gi|803568669|ref|WP_046077412.1|	27.5	207	238	648	1.12e-15	74.7
k141_40076_3	SARG|gi|446110352|ref|WP_000188207.1|	27.5	207	238	648	1.12e-15	74.7
k141_40076_3	SARG|YP_002382193	27.5	207	238	648	1.12e-15	74.7
k141_40076_3	SARG|gi|803575554|ref|WP_046081557.1|	27.5	207	238	648	1.12e-15	74.7
k141_40076_3	SARG|gi|446110351|ref|WP_000188206.1|	27.5	207	238	648	1.12e-15	74.7
k141_40076_41	SARG|gi|445996710|ref|WP_000074565.1|	28.1	253	506	309	2.18e-16	79.0
k141_40076_41	SARG|gi|445996722|ref|WP_000074577.1|	30.0	253	506	309	2.18e-16	79.0
k141_40076_41	SARG|gi|445996719|ref|WP_000074574.1|	31.1	225	506	309	2.93e-16	78.6
k141_40076_41	SARG|gi|445996723|ref|WP_000074578.1|	29.6	253	506	309	2.93e-16	78.6
k141_40076_41	SARG|gi|895808656|emb|COR83787.1|	28.1	253	506	309	3.94e-16	78.2
k141_40076_41	SARG|gi|500448961|gb|EOP61695.1|	28.8	250	506	306	5.12e-16	77.8
k141_40076_41	SARG|gi|500465078|gb|EOP76697.1|	28.8	250	506	306	5.12e-16	77.8
k141_40076_41	SARG|gi|507035724|ref|WP_016107411.1|	28.8	250	506	309	5.30e-16	77.8
k141_40076_41	SARG|gi|445996724|ref|WP_000074579.1|	29.6	253	506	309	5.30e-16	77.8
k141_40076_41	SARG|gi|445996729|ref|WP_000074584.1|	28.1	253	506	309	5.30e-16	77.8
k141_112395_13	SARG|gb|AAF89148.1|ARO:3004813|GOB-6	30.8	91	201	252	1.16e-06	46.6
k141_112395_13	ResF|blaGOB-6_1_AF189292_1	30.8	91	201	290	1.32e-06	46.6
k141_112395_13	NCBI|WP_069147617.1|1|1|blaGOB-6|blaGOB|hydrolase|2|||subclass_B3_metallo-beta-lactamase_GOB-6|AMR|beta-lactam	30.8	91	201	290	1.32e-06	46.6
k141_112395_13	SARG|gb|WP_078793281.1|ARO:3005693|GOB-44	33.7	92	201	290	1.78e-06	46.2
k141_112395_13	SARG|gb|AAF89152.1|ARO:3004809|GOB-2	30.8	91	201	252	2.13e-06	45.8
k141_112395_13	SARG|AF090141.1.gene1.p1	30.8	91	201	290	2.41e-06	45.8
k141_112395_13	SARG|gb|WP_078797000.1|ARO:3005682|GOB-33	32.6	92	201	290	2.41e-06	45.8
k141_112395_13	SARG|gb|WP_034845394.1|ARO:3005689|GOB-40	30.8	91	201	290	2.41e-06	45.8
k141_112395_13	ResF|blaGOB-2_1_AF189296_1	30.8	91	201	290	2.41e-06	45.8
k141_112395_13	SARG|gb|WP_102793805.1|ARO:3005694|GOB-45	30.8	91	201	290	2.41e-06	45.8
k141_112395_27	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_112395_27	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_112395_27	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_112395_27	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_112395_27	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_112395_27	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_112395_27	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_112395_27	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_112395_27	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_112395_27	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	201	270	655	1.73e-09	57.0
k141_71086_19	SARG|gb|APB03219.1|ARO:3003986|TaeA	30.4	539	534	648	1.85e-70	236
k141_71086_19	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	538	534	655	4.28e-64	219
k141_71086_19	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	538	534	655	5.95e-64	219
k141_71086_19	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	538	534	655	5.95e-64	219
k141_71086_19	SARG|gb|AKA86814|ARO:3003746|optrA	27.1	538	534	655	5.95e-64	219
k141_71086_19	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.5	539	534	655	8.26e-64	219
k141_71086_19	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	538	534	655	8.26e-64	219
k141_71086_19	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	538	534	655	1.59e-63	218
k141_71086_19	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	538	534	655	1.59e-63	218
k141_71086_19	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.1	538	534	655	1.59e-63	218
k141_71086_26	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	34.9	258	365	356	2.77e-32	123
k141_71086_26	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	34.3	251	365	355	5.22e-32	122
k141_71086_26	SARG|BAE96115	34.3	251	365	355	5.22e-32	122
k141_71086_26	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	34.9	189	365	209	8.43e-24	96.7
k141_71086_32	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	26.2	290	457	593	3.37e-12	67.4
k141_71163_20	megares|MEG_7165|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.6	442	603	639	2.30e-23	103
k141_71163_20	SARG|AAR29485	25.7	443	603	639	5.37e-23	102
k141_71163_20	SARG|gi|544707441|ref|WP_021137831.1|	25.7	443	603	639	5.37e-23	102
k141_71163_20	megares|MEG_7166|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.1	442	603	639	5.37e-23	102
k141_71163_20	SARG|gi|672386269|gb|AIJ27535.1|	25.7	443	603	639	7.13e-23	102
k141_71163_20	megares|MEG_7164|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.3	442	603	639	9.47e-23	101
k141_71163_20	SARG|AAV80410	24.0	437	603	651	1.29e-22	101
k141_71163_20	SARG|WP_002857791.1	24.9	442	603	639	1.67e-22	100
k141_71163_20	SARG|L42544.gene.p01	24.0	437	603	651	1.72e-22	100
k141_71163_20	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.1	433	603	629	2.86e-22	100
k141_71163_21	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	27.0	500	697	633	1.42e-37	147
k141_71185_5	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	29.9	261	294	346	1.52e-19	86.3
k141_153119_21	CARD|gb|AAL19308.1|ARO:3000504|golS	32.9	79	272	154	5.94e-08	50.1
